GenMark Diagnostics (GNMK) 10-K 28 Feb 17 2015 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Feb. 24, 2017	Jun. 30, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	GenMark Diagnostics, Inc.
Entity Central Index Key	1,487,371
Document Type	10-K
Document Period End Date	Dec. 31, 2016
Amendment Flag	false
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding		47,051,202
Entity Public Float			$ 350,814

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Current assets
Cash and cash equivalents	$ 15,959	$ 35,385
Marketable securities	25,607	10,080
Accounts receivable, net of allowances of $2,727 and $2,702, respectively	9,048	6,847
Inventories	6,633	3,054
Prepaid expenses and other current assets	1,202	591
Total current assets	58,449	55,957
Property and equipment, net	18,268	11,396
Intangible assets, net	2,670	2,376
Restricted cash	758	758
Other long-term assets	179	180
Total assets	80,324	70,667
Current liabilities
Accounts payable	8,703	4,376
Accrued compensation	5,650	3,861
Loan payable	7,935	(373)
Other current liabilities	4,133	2,725
Total current liabilities	26,421	10,589
Long-term liabilities
Deferred rent	3,652	1,257
Long-term Debt, Excluding Current Maturities	11,880	9,890
Other non-current liabilities	220	334
Total liabilities	42,173	22,070
Commitments and contingencies—See note 7
Stockholders’ equity
Preferred stock, $0.0001 par value; 5,000 authorized, none issued	0	0
Common stock, $0.0001 par value; 100,000 authorized; 42,551 and 41,859 shares issued and outstanding as of December 31, 2015 and December 31, 2014, respectively	4	4
Additional paid-in capital	393,322	353,233
Accumulated deficit	(355,270)	(304,669)
Accumulated other comprehensive income (loss)	95	29
Total stockholders’ equity	38,151	48,597
Total liabilities and stockholders’ equity	$ 80,324	$ 70,667

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Accounts receivable - net of allowance	$ 2,740	$ 2,727
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, authorized	100,000,000	100,000,000
Common stock, issued	46,554,000	42,551,000
Common stock, outstanding	46,554,000	42,551,000
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, authorized	5,000,000	5,000,000

CONSOLIDATED STATEMENT OF COMPR

CONSOLIDATED STATEMENT OF COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Other Comprehensive Income (Loss), Net of Tax	$ (50,535)	$ (42,158)	$ (38,283)
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax	77	36	0
Revenue
Product revenue	48,914	39,029	30,328
License and other revenue	360	382	266
Total revenue	49,274	39,411	30,594
Cost of revenue	19,700	15,317	13,127
Gross profit	29,574	24,094	17,467
Operating expenses
Sales and marketing	14,734	14,385	12,629
General and administrative	14,363	13,772	12,069
Research and development	49,458	37,472	31,823
Total operating expenses	78,555	65,629	56,521
Loss from operations	(48,981)	(41,535)	(39,054)
Other income (expense)
Interest income	176	125	244
Interest expense	(1,536)	(880)	(20)
Other income (expense)	(160)	133	(6)
Total other income (expense)	(1,520)	(622)	218
Loss before provision for income taxes	(50,501)	(42,157)	(38,836)
Income tax expense (benefit)	100	40	(573)
Net loss	$ (50,601)	$ (42,197)	$ (38,263)
Net loss per share, basic and diluted	$ (1.15)	$ (1)	$ (0.93)
Weighted average number of shares outstanding	44,100	42,157	41,346
Other comprehensive loss
Net loss	$ (50,601)	$ (42,197)	$ (38,263)
Net unrealized losses on marketable securities, net of tax	$ (11)	$ 3	$ (20)

CONSOLIDATED STATEMENT OF STOCK

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($) shares in Thousands	Total	Common Stock	Additional paid-in capital	Accumulated other comprehensive loss	Accumulated deficit
Beginning balance at Dec. 31, 2013	$ 109,168,000	$ 4,000	$ 333,363,000	$ 10,000	$ (224,209,000)
Beginning Balance, Shares at Dec. 31, 2013		41,520
Stock-based compensation expense	5,796,000		5,796,000
Employee purchases	$ 812,000		812,000
Shares issued	89
Shares issued under stock-based compensation plans, net of cancellations	$ 531,000		531,000
Shares issued under stock-based compensation plans, net of cancellations, Shares		101
Net loss	(38,263,000)				(38,263,000)
Net unrealized losses on marketable securities, net of tax	(20,000)			(20,000)
Ending Balance at Dec. 31, 2014	78,024,000	$ 4,000	340,502,000	(10,000)	(262,472,000)
Ending Balance, Shares at Dec. 31, 2014		41,859
Issuance of stock in lieu of accrued bonuses	863,000
Issuance of stock in lieu of accrued bonuses, Shares		105
Stock-based compensation expense			9,995,000
Employee purchases			884,000
Shares issued		122
Restricted stock awards issued, net of cancellations, Shares		284
Shares issued under stock-based compensation plans, net of cancellations			989,000
Shares issued under stock-based compensation plans, net of cancellations, Shares		181
Net loss	(42,197,000)				(42,197,000)
Temporary Equity, Foreign Currency Translation Adjustments	36,000
Net unrealized losses on marketable securities, net of tax	3,000
Ending Balance at Dec. 31, 2015	48,597,000	$ 4,000	353,233,000	29,000	(304,669,000)
Ending Balance, Shares at Dec. 31, 2015		42,551
Issuance of stock in lieu of accrued bonuses	$ 364,000
Issuance of stock in lieu of accrued bonuses, Shares	28
Stock-based compensation expense	$ 9,236,000		9,236,000
Employee purchases	921,000		921,000
Shares issued		138
Restricted stock awards issued, net of cancellations	0		0
Restricted stock awards issued, net of cancellations, Shares		421
Issuance of common stock, net of offering expenses			28,856,000
Issuance of common stock, net of offering expenses, Shares		3,317
Shares issued under stock-based compensation plans, net of cancellations	712,000		712,000
Shares issued under stock-based compensation plans, net of cancellations, Shares		99
Net loss	(50,601,000)				(50,601,000)
Temporary Equity, Foreign Currency Translation Adjustments	77,000
Net unrealized losses on marketable securities, net of tax	(11,000)			(11,000)
Ending Balance at Dec. 31, 2016	$ 38,151,000	$ 4,000	$ 393,322,000	$ 95,000	$ (355,270,000)
Ending Balance, Shares at Dec. 31, 2016		46,554

CONSOLIDATED STATEMENT OF CASH

CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Cash flows from operating activities
Net loss	$ (50,601)	$ (42,197)	$ (38,263)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	3,916	3,405	2,656
Accretion (Amortization) of Discounts and Premiums, Investments	89	180	702
Amortization of premiums on investments	388	285	0
Stock-based compensation	9,236	9,995	5,796
Provision for bad debt	13	25	0
Non-cash inventory adjustments	134	594	450
Gain on sale of investment in preferred stock	(9)	(223)	0
Other non-cash adjustments	145	186	185
Changes in operating assets and liabilities:
Accounts receivable	(2,250)	(1,983)	(2,030)
Inventories	(3,450)	(1,286)	(229)
Prepaid expenses and other assets	(613)	(36)	(184)
Accounts payable	4,105	(757)	85
Accrued compensation	2,172	(458)	1,797
Other liabilities	1,088	355	(537)
Net cash used in operating activities	(35,637)	(31,915)	(29,572)
Investing activities
Payments for intellectual property licenses	(1,500)	(550)	(350)
Purchases of property and equipment	(7,000)	(3,756)	(5,726)
Purchases of available-for-sale securities	(33,688)	(22,646)	(28,054)
Proceeds from sales of marketable securities	8,015	223	7,497
Maturities of marketable securities	10,050	46,050	56,050
Net cash provided by (used in) investing activities	(24,123)	19,321	29,417
Financing activities
Proceeds from issuance of common stock	30,920	884	812
Costs incurred in conjunction with public offering	(1,143)	0	0
Principal repayment of borrowings	(40)	(22)	(56)
Payments of Debt Issuance Costs	(90)	(718)	0
Proceeds from borrowings	10,000	10,000	0
Proceeds from stock option exercises	712	989	531
Net cash provided by financing activities	40,359	11,133	1,287
Effect of Exchange Rate on Cash and Cash Equivalents	(25)	(9)	0
Net increase (decrease) in cash and cash equivalents	(19,426)	(1,470)	1,132
Cash and cash equivalents at beginning of year	35,385	36,855
Cash and cash equivalents at end of year	15,959	35,385	36,855
Non-cash investing and financing activities:
Transfer of systems from property and equipment into inventory	263	225	256
Property and equipment costs incurred but not paid included in accounts payable	1,159	146	124
Intellectual property acquisition included in accrued expenses	0	800	550
Supplemental cash flow information:
Cash paid for interest	1,130	572	20
Cash received for interest	266	305	244
Cash paid for income taxes, net	$ 65	$ 10	$ 24

Organization and Basis of Prese

Organization and Basis of Presentation	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and basis of presentation	Organization and basis of presentation Organization GenMark Diagnostics, Inc., the Company or GenMark, was formed by Osmetech plc, or Osmetech, as a Delaware corporation in February 2010, and had no operations prior to its initial public offering, or the IPO, which was completed in June 2010. Immediately prior to the closing of the IPO, GenMark acquired all of the outstanding ordinary shares of Osmetech in a reorganization, accounted for in a manner similar to a pooling-of-interests, under the applicable laws of the United Kingdom. As a result of the reorganization, all of the issued ordinary shares in Osmetech were cancelled in consideration of (i) the issuance of common stock of GenMark to the former shareholders of Osmetech and (ii) the issuance of new shares in Osmetech to GenMark. Following the reorganization, Osmetech became a subsidiary controlled by GenMark, and the former shareholders of Osmetech received shares of GenMark. Any historical discussion of GenMark relates to Osmetech and its consolidated subsidiaries prior to the reorganization. In September 2012, GenMark placed Osmetech into liquidation to simplify its corporate structure. The liquidation of Osmetech was completed in the fourth quarter of 2013. Segment Reporting The Company currently operates as one operating segment. Operating segments are defined as components of an enterprise for which separate financial information is evaluated regularly by the chief operating decision maker, who is the chief executive officer, in deciding how to allocate resources and assessing performance. The Company’s business operates in one operating segment because the Company’s chief operating decision maker evaluates the Company’s financial information and resources and assesses the performance of these resources on a consolidated basis. Since the Company operates in one operating segment, all required financial segment information can be found in the consolidated financial statements. Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, or U.S. GAAP, requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the notes thereto. The Company’s significant estimates included in the preparation of the financial statements are related to accounts receivable, inventories, property and equipment, intangible assets, employee related compensation accruals, warranty liabilities, tax valuation accounts and stock-based compensation. Actual results could differ from those estimates. Basis of Presentation The accompanying financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net losses from operations since its inception and has an accumulated deficit of $355,270,000 at December 31, 2016 . Management expects operating losses to continue through the foreseeable future. The Company's ability to transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support its cost structure through expanding its product offerings and consequently increasing its product revenues. Cash, cash equivalents, restricted cash, and investments at December 31, 2016 totaled $41,566,000 . The Company has prepared cash flow forecasts which indicate, based on the Company’s current cash resources available, that the Company will have sufficient resources to fund its business for at least the next 12 months from the date of this filing. The accompanying consolidated financial statements have been prepared in accordance with U.S. GAAP and applicable regulations of the Securities and Exchange Commission, or the SEC. Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Summary of significant accounting policies	Summary of Significant Accounting Policies and Significant Accounts Cash and Cash Equivalents and Marketable Securities Cash and cash equivalents consist of cash on deposit with banks, money market instruments and certificates of deposit with original maturities of three months or less at the date of purchase. Marketable securities consist of certificates of deposits that mature in greater than three months . Marketable securities are accounted for as "available-for-sale" with the carrying amounts reported in the balance sheets stated at cost, which approximates their fair market value, with unrealized gains and losses, if any, reported as a separate component of stockholders' equity and included in comprehensive loss. Restricted Cash Restricted cash represents amounts designated for uses other than current operations and includes $758,000 at December 31, 2016 held as security for the Company’s letter of credit with Banc of California. Fair Value of Financial Instruments The Company uses a fair value hierarchy with three levels of inputs, of which the first two are considered observable and the last unobservable, to measure fair value: • Level 1 — Quoted prices in active markets for identical assets or liabilities. • Level 2 — Inputs, other than Level 1, that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The carrying amounts of financial instruments such as accounts receivable, prepaid expenses and other current assets, accounts payable, and accrued liabilities approximate the related fair values due to the short-term maturities of these instruments. Receivables Accounts receivable consist of amounts due to the Company for sales to customers and are recorded net of an allowance for doubtful accounts. The allowance for doubtful accounts is determined based on an assessment of the collectability of specific customer accounts, the aging of accounts receivable, and a reserve for unknown items based upon the Company’s historical experience. The allowance for doubtful accounts as of December 31, 2016 , is as follows (in thousands): Allowance for doubtful accounts Balance December 31, 2014 $ 2,702 Provision for doubtful accounts 25 Balance December 31, 2015 $ 2,727 Provision for doubtful accounts 13 Balance December 31, 2016 $ 2,740 The Company has included $2,702,000 in the allowance for doubtful accounts as of December 31, 2016 and 2015 for past due amounts from its former customer, Natural Molecular Testing Corporation. Inventories Inventories are stated at the lower of cost (first-in, first-out) or net realizable value and include direct labor, materials, and manufacturing overhead. The Company periodically reviews inventory for evidence of slow-moving or obsolete parts, and writes inventory down to net realizable value, as needed. This write-down is based on management’s review of inventories on hand, compared to estimated future usage and sales, shelf-life assumptions, and assumptions about the likelihood of obsolescence. If actual market conditions are less favorable than those projected by the Company, additional inventory write-downs may be required. Inventory impairment charges establish a new cost basis for inventory and charges are not reversed subsequently to income, even if circumstances later suggest that increased carrying amounts are recoverable. Property and Equipment-net Property, equipment and leasehold improvements are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets, which are: Machinery and laboratory equipment 3 – 5 years Instruments 4 – 5 years Office equipment 3 – 7 years Leasehold improvements over the shorter of the remaining life of the lease or the useful economic life of the asset Property and equipment includes diagnostic instruments used for sales demonstrations or placed with customers under several types of arrangements, including performance evaluation programs, or PEPs, and reagent rental agreements. PEPs are placed with customers for evaluation periods of up to three months and the Company retains title to the instruments under these arrangements. Maintenance and repair costs are expensed as incurred. Intangible Assets Intangible assets are comprised of licenses or sublicenses to technology covered by patents owned by third parties, and are amortized on a straight-line basis over the expected useful lives of these assets, which is generally 10 years. Amortization of licenses typically begins upon the Company obtaining access to the licensed technology and is recorded in cost of revenues for licenses supporting commercialized products. The amortization of licenses to technology supporting products in development is recorded in research and development expenses. Impairment of Long-Lived Assets The Company assesses the recoverability of long-lived assets, including intangible assets, by periodically evaluating the carrying value whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If impairment is indicated, the Company writes down the carrying value of the asset to its estimated fair value. This fair value is primarily determined based on estimated discounted cash flows. The Company did not recognize any impairment charges during the years ended December 31, 2016 and 2015. Revenue Recognition The Company recognizes revenue from product sales and contract arrangements, net of discounts and sales related taxes. The Company recognizes revenue from product sales when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable and collectability is reasonably assured. The Company offers customers the choice to either purchase a system outright or to receive a system free of charge in exchange for an annual minimum purchase commitment for diagnostic test cartridges. When a system is sold, the Company generally recognizes revenue upon shipment of the unit, however, if the end user already has the instrument being purchased installed at its location, revenue is recognized when the revenue recognition terms other than delivery have been satisfied. When a system is placed free of charge under a “reagent rental” agreement, the Company retains title to the equipment and it remains capitalized on the balance sheet under property and equipment. Under reagent rental agreements, the Company’s customers pay an additional system rental fee for each test cartridge purchased which varies based on the monthly volume of test cartridges purchased. The system rental fee and diagnostic test cartridges are recognized as contingent rental payments and are included in product revenue in the Company’s consolidated financial statements. The Company has not had significant product returns and is not contractually obligated to accept returns unless such returns are related to warranty provisions. The Company generally does not accept reagent product returns, mainly due to FDA regulations, and does not offer volume rebates or provide price protection. The Company enters into PEP agreements pursuant to which an instrument is installed on the premises of a pre-qualified customer for the purpose of allowing the customer to evaluate the instrument’s functionality over an extended trial period. The customer is generally required to purchase a minimum quantity of reagents and, at the end of the evaluation period, must purchase or return the instrument or sign a reagent rental agreement. Revenues related to royalties received from licenses are recognized evenly over the contractual period to which the license relates. In those cases where the Company bills shipping and handling costs to customers, the amounts billed are included in product revenue. In 2016 and 2015, Laboratory Corporation of America, Inc. represented 27% and 17% , respectively, of the Company's total revenue. In 2014, no single customer represented more than 10% of the Company's total revenue. Product Warranties The Company generally offers a one -year warranty for its instruments sold to customers and up to a sixty day warranty for reagents and provides for the estimated cost of the product warranty at the time the system sale is recognized. Factors that affect the Company’s warranty reserves include the number of units sold, historical and anticipated rates of warranty repairs and the cost per repair. The Company periodically assesses the adequacy of the warranty reserve and adjusts the amount as necessary. Product warranty reserve activity for the years ended December 31, 2016 , 2015 and 2014 is as follows (in thousands): 2016 2015 2014 Beginning balance $ 118 $ 195 $ 226 Warranty expenses incurred (421 ) (430 ) (608 ) Provisions 522 353 577 Ending balance $ 219 $ 118 $ 195 Research and Development Costs The Company expenses all research and development costs in the periods in which they are incurred unless there is alternative future use that supports the capitalization of an asset. Income Taxes Current income tax expense is the amount of income taxes expected to be payable for the current year. A deferred income tax liability or asset is established for the expected future tax consequences resulting from the differences in financial reporting and tax bases of assets and liabilities. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized. A full valuation allowance has been recorded against the Company’s net deferred tax assets due to the uncertainty surrounding the Company’s ability to utilize these assets in the future. The Company provides for uncertain tax positions when such tax positions do not meet the recognition thresholds or measurement standards prescribed by the authoritative guidance on income taxes. Amounts for uncertain tax positions are adjusted in periods when new information becomes available or when positions are effectively settled. The Company recognizes accrued interest related to uncertain tax positions as a component of income tax expense. A tax position that is more likely than not to be realized is measured at the largest amount of tax benefit that is greater than 50% likely of being realized upon settlement with the taxing authority that has full knowledge of all relevant information. Measurement of a tax position that meets the more likely than not threshold considers the amounts and probabilities of the outcomes that could be realized upon settlement using the facts, circumstances and information available at the reporting date. Stock-Based Compensation The Company recognizes stock-based compensation expense related to stock options, shares purchased under the Company's ESPP, restricted stock awards, restricted stock units and market-based stock units granted to employees and directors in exchange for services. The compensation expense is based on the fair value of the applicable award utilizing various assumptions regarding the underlying attributes of the award. The stock-based compensation expense is recorded in cost of revenues, sales and marketing, research and development, and/or general and administrative expenses based on the employee's respective function. The estimated fair value of stock granted, net of forfeitures expected to occur during the vesting period, is amortized as compensation expense that approximates straight-line expense to reflect vesting as it occurs. The stock option expense is derived from the Black-Scholes Option Pricing Model that uses several judgment-based variables to calculate the expense. The market-based stock expense is derived from the Monte Carlo Simulation Valuation. The inputs utilized in the valuation of the stock-based awards include the following factors: • Expected Term. Expected term represents the period that the stock-based awards are expected to be outstanding and is determined by using the simplified method. • Expected Volatility . Expected volatility represents the expected volatility in the Company’s stock price over the expected term of the option or market-based award and is determined by review of the Company’s and similar companies’ historical experience. • Expected Dividend . The valuation methods required a single expected dividend yield as an input. The Company assumed no dividends as it has never paid dividends and has no current plans to do so. • Risk-Free Interest Rate. The risk-free interest rate is based on published U.S. Treasury rates in effect at the time of grant for periods corresponding with the expected term of the option or market-based award. The compensation expense related to the grant of restricted stock awards or units is calculated as the fair market value of the stock on the grant date as further adjusted to reflect expected forfeitures. Foreign Currency Translation During 2015, the Company established foreign subsidiaries with currencies other than the U.S. Dollar. The assets and liabilities of the Company's entities outside the U.S. are translated into U.S. Dollars based on the foreign currency exchange rates at the end of each period, while revenues and expenses are translated at weighted average exchange rates during the applicable period. Gains or losses resulting from these foreign currency translations of the Company's assets and liabilities are recorded in accumulated comprehensive loss in the consolidated balance sheets. Foreign currency translation impacts recorded in accumulated other comprehensive loss for the year ended December 31, 2016 and 2015 was $77,000 and $36,000 , respectively. Transactions in foreign currencies were recognized using the rate of exchange prevailing at the date of the transaction. Foreign exchange losses, which are included in the accompanying consolidated statements of operations, totaled $169,000 , $91,000 and $9,000 for the years ended December 31, 2016 , 2015 and 2014 , respectively, and relate primarily to transactions denominated in Euros. Net Loss per Common Share Basic net loss per share is calculated by dividing loss available to stockholders of our common stock (the numerator) by the weighted average number of shares of the Company's common stock outstanding during the period (the denominator). Shares issued during the period and shares reacquired during the period are weighted for the portion of the period that they were outstanding. Diluted loss per share is calculated in a similar way to basic loss per share except that the denominator is increased to include the number of additional shares that would have been outstanding if the dilutive potential shares had been issued unless the effect would be anti-dilutive. The calculations of diluted net loss per share for the years ended December 31, 2016 , 2015 and 2014 did not include the effects of the following stock options or other unvested equity awards which were outstanding as of the end of each year because the inclusion of these securities would have been anti-dilutive (in thousands). Year Ended December 31, 2016 2015 2014 Options outstanding to purchase common stock 2,570 3,004 2,479 Other unvested equity awards 2,000 1,267 948 Total 4,570 4,271 3,427 Concentration of Risk Financial instruments which potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents, short-term investment securities, and accounts receivable. We limit our exposure to credit loss by placing our cash with high credit quality financial institutions. We have established guidelines relative to diversification of our cash and investment securities and their maturities that are intended to secure safety and liquidity. The following table summarizes customers who accounted for 10% or more of net accounts receivable: December 31, 2016 2015 Laboratory Corporation of America, Inc. 33 % 35 % Comprehensive Loss The Company has the option to present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single continuous statement of comprehensive income or in two separate but consecutive statements. The Company’s comprehensive loss comprises net losses, unrealized gains and losses on available for sale securities, and foreign currency translation. Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standard Board, or the FASB, or other standard setting bodies that the Company adopts as of the specified effective date. The Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. In March 2016, the FASB issued Accounting Standards Update, or ASU, 2016-09, Improvements to Employee Share-Based Payment Accounting. This guidance simplifies how several aspects of share-based payments are accounted for and presented in the financial statements. This guidance is effective for the Company beginning January 1, 2017 and the Company will adopt this ASU in the first quarter of 2017. The Company has excess tax benefits for which a benefit could not be previously recognized of approximately $1,979,000 . Upon adoption, the balance of the unrecognized excess tax benefits will be reversed with the impact recorded to retained earnings, including any change to the valuation allowance as a result of adoption. Due to the full valuation allowance on the Company's U.S. deferred tax assets, the Company does not expect any impact to the financial statements as a result of this adoption. In February 2016, the FASB issued ASU 2016-02, Leases. This ASU outlines a comprehensive lease accounting model and supersedes the current lease guidance. The new guidance requires lessees to recognize lease liabilities and corresponding right-of-use assets for all leases with lease terms of greater than 12 months. It also changes the definition of a lease and expands the disclosure requirements of lease arrangements. The new guidance must be adopted using the modified retrospective approach and will be effective for the Company starting in the first quarter of 2019, with early adoption permitted. The Company is evaluating the effects adoption will have on its consolidated financial statements. The Company expects this adoption will result in a material increase in the assets and liabilities on our consolidated balance sheets and will likely have an immaterial impact on our consolidated statements of comprehensive loss. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, an updated standard on revenue recognition. ASU 2014-09 provides enhancements to the quality and consistency of how revenue is reported by companies while also improving comparability in the financial statements of companies reporting using International Financial Reporting Standards or U.S. GAAP. The main purpose of the new standard is for companies to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration to which a company expects to be entitled in exchange for those goods or services. The new standard also will result in enhanced disclosures of revenue, provide guidance for transactions that were not previously addressed comprehensively, and improve guidance for multiple-element arrangements. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers: Deferral of the Effective Date, which deferred the effective date of the new revenue standard for periods beginning after December 15, 2016 to December l5, 2017, with early adoption permitted but not earlier than the original effective date. Accordingly, the updated standard is effective for the Company in the first quarter of fiscal 2018. The Company is currently evaluating the overall impact this standard will have on our consolidated financial statements, as well as the expected timing and method of adoption. Based on our preliminary assessment, the Company does not anticipate a material impact on its financial statements. The Company is continuing this assessment, which may identify other impacts.

Intangible Assets, net

Intangible Assets, net	12 Months Ended
	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets, net	Intangible Assets, net Intangible assets as of December 31, 2016 and 2015 consisted of the following (in thousands): December 31, 2016 December 31, 2015 Gross carrying amount Accumulated amortization Net carrying amount Gross carrying amount Accumulated amortization Net carrying amount Licensed intellectual property $ 4,250 $ (1,580 ) $ 2,670 $ 3,550 $ (1,174 ) $ 2,376 In March 2012, the Company entered into a license agreement with Caliper Life Sciences Inc., or Caliper, pursuant to which the Company obtained a non-exclusive license under Caliper’s microfluidics patent portfolio. In consideration for the license, the Company agreed to pay Caliper $400,000 in up-front payments recorded as an intangible asset on the Company’s balance sheet plus certain sales-based milestone payments, as well as a royalty on the sale of certain products. As part of the agreement, the Company obtained an unconditional release from any and all claims based upon any alleged infringement of the licensed patents prior to the effective date of the agreement. The Company met sales-based milestones in March 2013, March 2014 and August 2015 triggering the payment of $450,000 , $550,000 , and $800,000 , respectively, which were made after the fiscal year during which the respective milestone was achieved. In July 2012, the Company entered into a development collaboration and license agreement with Advanced Liquid Logic, Inc., or ALL, which was acquired by Illumina, Inc. in July 2013. Under the terms of the agreement, the Company established a collaborative program to develop in-vitro diagnostic products incorporating ALL’s proprietary electrowetting technology in conjunction with the Company’s electrochemical detection technology. The Company paid ALL an upfront license payment of $250,000 and agreed to pay up to $1,750,000 in potential additional milestone payments. Pursuant to the agreement, as amended, the Company will be obligated to pay to ALL a royalty consisting of a low- to mid-single digit percent of net sales of designated licensed products containing ALL components. The Company met certain milestones in August 2013, June 2014 and September 2016 resulting in the payment of $200,000 , $350,000 and $700,000 , respectively, to ALL. Intellectual property licenses had a weighted average remaining amortization period of 5.40 years as of December 31, 2016 . Amortization expense for intangible assets amounted to $406,000 , $294,000 and $227,000 for the years ended December 31, 2016 , 2015 and 2014 , respectively. Estimated future amortization expense for these licenses is as follows (in thousands): Years Ending December 31, Future Amortization Expense 2017 $ 497 2018 497 2019 497 2020 497 2021 497 Thereafter 185 Total $ 2,670

Stockholders' Equity (Notes)

Stockholders' Equity (Notes)	12 Months Ended
	Dec. 31, 2016
Equity [Abstract]
Stockholders' Equity	Stockholders’ Equity On June 14, 2016, the Company entered into an Equity Distribution Agreement, or the Distribution Agreement, with Canaccord Genuity Inc., as sales agent, or Canaccord, pursuant to which the Company could, at its discretion, offer and sell, from time to time, through Canaccord shares of its common stock having an aggregate offering price of up to $30,000,000 . Under the Distribution Agreement, Canaccord could sell shares by any method deemed to be an “at-the-market” offering as defined in Rule 415 under the Securities Act or any other method permitted by law, including in privately negotiated transactions. The Company began sales under the Distribution Agreement in August 2016 pursuant to an effective shelf registration statement on Form S-3 previously filed with the SEC. During the three months ended September 30, 2016, the Company sold 3.3 million shares of common stock, at an average per share price of $9.04 , for aggregate gross proceeds of $30,000,000 . The Company incurred $1,143,000 in related transaction costs, comprising commissions paid to Canaccord of 3.0% of the aggregate gross proceeds from each sale of shares occurring pursuant to the Distribution Agreement, or $900,000 , and $243,000 in additional miscellaneous expenses.

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2016
Compensation Related Costs [Abstract]
Stock-Based Compensation	Stock-Based Compensation In 2010, the Company adopted the 2010 Equity Incentive Plan, or the 2010 Plan, which provides for the grant of incentive and nonstatutory stock options, restricted stock, stock appreciation rights, restricted stock units, restricted stock bonuses and other stock-based awards. Employee participation in the 2010 Plan is at the discretion of the compensation committee of the board of directors of the Company. All stock options granted under the 2010 Plan are exercisable at a price equal to the closing quoted market price of the Company’s shares on the NASDAQ Global Market on the date of grant and generally vest over a period of between one and four years. The Company estimates potential forfeitures of stock-based award grants and adjusts compensation cost recorded accordingly. The estimate of forfeitures is based on historical forfeiture experience and is adjusted over the requisite service period to the extent that actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures will be recognized through a cumulative catch-up adjustment in the period of evaluation and will also impact the amount of stock compensation expense to be recognized in future periods. Stock options are generally exercisable for a period up to 10 years after grant and are forfeited if employment is terminated before the options vest. As of December 31, 2016 , there were 79,455 shares available for future grant of awards under the 2010 Plan. The following table summarizes stock option activity during the year ended December 31, 2016 : Number of shares Weighted average exercise price Outstanding at December 31, 2015 3,004,011 $ 9.74 Granted 5,000 $ 4.70 Exercised (98,941 ) $ 7.20 Forfeitures (340,520 ) $ 11.96 Outstanding at December 31, 2016 2,569,550 $ 9.53 Vested and expected to vest at December 31, 2016 2,490,256 $ 9.45 Exercisable at December 31, 2016 1,937,739 $ 8.75 The weighted average fair value of options granted during the years ended December 31, 2016 , 2015 and 2014 was $2.27 , $6.02 and $7.45 per share, respectively. Options that were exercisable as of December 31, 2016 had a remaining weighted average contractual term of 5.67 years and an aggregate intrinsic value of $7,036,000 . As of December 31, 2016 , there was $3,323,000 of unrecognized compensation cost related to stock options, which is expected to be recognized over a weighted average period of 1.57 years. The intrinsic value of options exercised during the years ended December 31, 2016 , 2015 and 2014 was $896,000 , $938,000 and $584,000 , respectively. As of December 31, 2016 , there were 2,569,550 stock options outstanding, which had a remaining weighted average contractual term of 6.20 years and an aggregate intrinsic value of $7,532,000 . Valuation of Stock-Based Awards The assumptions used in the valuation of stock-based awards for the years ended December 31, 2016 , 2015 and 2014 , are summarized in the following table: Years Ended December 31, 2016 2015 2014 Expected volatility (%) 51 % 49 % 69 % Expected life (years) 5.90 6.06 6.08 Risk free rate (%) 1.35 % 1.67 % 1.82 % Expected dividend yield (%) — % — % — % Restricted Stock Awards and Units In March 2013, the Company transitioned to granting restricted stock units under the 2010 Plan in lieu of granting restricted stock awards. The Company’s restricted stock activity for the year ended December 31, 2016 was as follows: Restricted Stock Awards Restricted Stock Units Number of shares Weighted Average Grant Date Fair Value Number of shares Weighted Average Grant Date Fair Value Unvested at December 31, 2015 32,837 $ 5.00 934,977 $ 12.66 Granted — $ — 1,580,273 $ 5.80 Vested (32,369 ) $ 4.91 (444,365 ) $ 11.79 Forfeitures (312 ) $ 11.19 (304,762 ) $ 7.65 Unvested at December 31, 2016 156 $ 11.19 1,766,123 $ 7.18 Restricted stock awards or units may be granted at the discretion of the compensation committee of the board of directors under the 2010 Plan in connection with the hiring or retention of personnel and are subject to certain conditions. Restrictions expire at certain dates after the grant date in accordance with specific provisions in the applicable award agreement. As of December 31, 2016 , there was $1,000 of unrecognized compensation cost related to restricted stock awards, which is expected to be recognized over a weighted average-period of 0.04 years. The total fair value of restricted stock awards that vested during the years ended December 31, 2016 , 2015 and 2014 was $190,000 , $580,000 and $3,466,000 , respectively. As of December 31, 2016 , there was $8,509,000 of unrecognized compensation cost related to restricted stock units, which is expected to be recognized over a weighted average period of 2.80 years. The total fair value of restricted stock units that vested during the years ended December 31, 2016 , 2015 and 2014 was $3,192,000 , $ 4,457,000 and $2,121,000 , respectively. The Company issued market-based stock units in February 2015 and February 2016, which may result in the recipient receiving shares of stock equal to up to 200% of the target number of units granted. The vesting and issuance of Company stock depends on the Company's stock performance as compared to the NASDAQ Composite Index over the three-year period following the grant. As of December 31, 2016 , there was $781,000 of unrecognized stock-based compensation expense related to these awards, which is expected to be recognized over a weighted average period of 1.75 years. The total fair value of market-stock units that vested during the years ended December 31, 2016 and 2015 was $ 2,433,000 and $29,000 , respectively. The Company’s market-based stock unit activity for the year ended December 31, 2016 was as follows: Market-Based Stock Units Number of Shares Weighted Average Grant Date Fair Value Unvested at December 31, 2015 136,730 18.07 Units granted 335,253 4.94 Vested (192,941 ) 8.01 Cancelled (56,269) 9.81 Unvested at December 31, 2016 222,773 7.34 The fair value of these market-based stock units was estimated on the date of grant using the Monte Carlo Simulation Valuation Model, which estimates the potential outcome of achieving the market condition based on simulated future stock prices, with the following assumptions for the year ended December 31, 2016 : 2016 2015 Expected volatility 49 % 45 % Risk-free interest rate 0.90 % 1.10 % Expected dividend — % — % Weighted average fair value $ 4.94 $ 18.07 The Company granted 43,200 performance-based restricted stock units in March 2014 with a grant date fair value of $12.30 per share. The vesting and issuance of Company stock pursuant to these awards depends on obtaining regulatory clearance of a designated number of ePlex products within a defined time. Stock-based compensation expense for performance-based awards is recognized when it is probable that the applicable performance criteria will be satisfied. The probability of achieving the relevant performance criteria is evaluated on a quarterly basis. On December 31, 2014 , 10,800 units were earned and vested with a total fair value of $147,000 . On each of December 31, 2016 and 2015 , 10,800 units were forfeited and cancelled as the related performance metrics were not achieved by such dates. As of December 31, 2016 , there was $133,000 in unrecognized stock-based compensation expense related to the remaining unvested awards. Employee Stock Purchase Plan Following the adoption of the ESPP by the Company’s board of directors in March 2013, the Company's stockholders approved the ESPP in May 2013 at the Company's Annual Meeting of Stockholders. A total of 650,000 shares of the Company’s common stock are reserved for issuance under the ESPP, which permits eligible employees to purchase common stock at a discount through payroll deductions. The price at which stock is purchased under the ESPP is equal to 85% of the fair market value of the common stock on the first or the last day of the offering period, whichever is lower. Generally, each offering under the ESPP will be for a period of six months as determined by the Company's board of directors; provided that no offering period may exceed 27 months . Employees may invest up to 10% of their gross compensation through payroll deductions. In no event may an employee purchase more than 1,500 shares of common stock during any six-month offering period. As of December 31, 2016 , there were 267,839 shares of common stock available for issuance under the ESPP. The ESPP is a compensatory plan as defined by the authoritative guidance for stock compensation. As a result, stock-based compensation expense related to the ESPP, calculated using the Black-Scholes model at the beginning of each six-month offering period, has been recorded during the year ended December 31, 2016 . A summary of ESPP activity for the years ended December 31, 2016 and 2015 is as follows (in thousands, except share, and per share data): Year Ended December 31, 2016 2015 Shares issued 138,058 122,245 Weighted average fair value of shares issued $ 6.67 $ 7.22 Employee purchases $ 921 $ 884 Stock-Based Compensation Expense Recognition Stock-based compensation was recognized in the consolidated statements of comprehensive loss as follows (in thousands): Years Ended December 31, 2016 2015 2014 Cost of revenue $ 258 $ 209 $ 73 Sales and marketing 2,329 3,050 1,848 Research and development 2,482 2,498 1,194 General and administrative 4,167 4,238 2,681 Stock-based compensation expense $ 9,236 $ 9,995 $ 5,796 No stock-based compensation was capitalized during the periods presented, and there was no unrecognized tax benefit related to stock-based compensation for the years ended December 31, 2016 , 2015 and 2014 , respectively.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company's income (loss) before provision (benefit) for income taxes for the years ended December 31, 2016, 2015, and 2014, respectively, was generated in the following jurisdictions (in thousands): Years Ended December 31, 2016 2015 2014 Domestic $ (50,651 ) $ (42,221 ) $ (37,766 ) Foreign 150 64 (1,070 ) Worldwide Income (Loss) $ (50,501 ) $ (42,157 ) $ (38,836 ) The components of income tax expense (benefit) were as follows for the years ended December 31, 2016 , 2015 , and 2014 , respectively (in thousands): Years Ended December 31, 2016 2015 2014 Current expense: U.S. federal $ (10 ) $ — $ — State 31 25 (573 ) Foreign (non-U.S. entities) 70 20 — Total current expense (benefit) $ 91 $ 45 $ (573 ) Deferred expense (benefit): U.S. Federal $ 4 $ — $ — State 1 — — Total deferred expense (benefit) $ 5 $ — $ — The components of net deferred income taxes consisted of the following at December 31, 2016 and 2015 , respectively (in thousands): As of December 31, 2016 2015 Deferred income tax assets: NOL and credit carryforwards $ 74,375 $ 59,907 Compensation accruals 4,660 3,952 Accruals and reserves 3,437 2,201 State tax provision 8 8 Inventory adjustments 996 559 Intangible assets 645 361 Other 144 5 Subtotal: deferred tax assets 84,265 66,993 Valuation allowance (82,481 ) (66,211 ) Total deferred tax assets 1,784 782 Deferred income tax liabilities: Depreciation (1,784 ) (782 ) Subtotal: deferred tax liabilities (1,784 ) (782 ) Net deferred tax assets $ — $ — A reconciliation of income tax expense to the amount computed by applying the statutory federal income tax rate to the loss from operations is summarized for the years ended December 31, 2016 , 2015 , and 2014 , respectively, as follows: Years Ended December 31, 2016 2015 2014 U.S. Federal statutory income tax rate 34.0 % 34.0 % 34.0 % Permanent differences (0.3 )% (0.1 )% (0.3 )% State taxes 2.3 % 2.4 % 2.6 % Executive compensation limitation (0.1 )% (0.8 )% (0.7 )% Stock-based compensation (3.5 )% (1.4 )% (1.5 )% Other (0.4 )% 2.1 % 0.3 % Valuation allowance (32.2 )% (36.9 )% (32.9 )% Total tax provision (0.2 )% (0.7 )% 1.5 % The Company had federal net operating loss (NOL) carryforwards available of approximately $206,900,000 as of December 31, 2016 after consideration of limitations under Section 382 of the Internal Revenue Code, or Section 382, as further described below. Additionally, the Company had state NOL carryforwards available of $165,000,000 as of December 31, 2016 . These federal and state NOLs may be used to offset future taxable income and will begin to expire in 2025 and 2017, respectively. Of the $206,900,000 and $165,000,000 of federal and state NOL carryforwards at December 31, 2016 , $5,402,000 represents excess tax benefits related to equity compensation which will result in an increase in equity if and when such excess benefits are ultimately realized. The future utilization of the Company’s NOL carryforwards to offset future taxable income may be subject to a substantial annual limitation as a result of changes in ownership by stockholders that hold 5% or more of the Company’s common stock . An assessment of such ownership changes under Section 382 was completed through December 31, 2016. As a result of this assessment, the Company determined that it experienced multiple ownership changes through 2016 which will limit the future utilization of NOL carryforwards. The Company has reduced its deferred tax assets related to NOL carryovers that are anticipated to expire unused as a result of ownership changes. These tax attributes have been excluded from deferred tax assets with a corresponding reduction of the valuation allowance with no net effect on income tax expense or the effective tax rate. Additionally, future ownership changes may further impact the utilization of existing NOLs. The Company has established a full valuation allowance for its deferred tax assets due to uncertainties that preclude it from determining that it is more likely than not that the Company will be able to generate sufficient taxable income to realize such assets. Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize the existing deferred tax assets. A significant piece of objective negative evidence evaluated was the cumulative loss incurred over the three year period ended December 31, 2016 . Such objective evidence limits the ability to consider other subjective evidence such as the Company's projections for future growth. Based on this evaluation, as of December 31, 2016 , a valuation allowance of $82,481,000 has been recorded in order to measure only the portion of the deferred tax asset that more likely than not will be realized. The amount of the deferred tax asset considered realizable, however, could be adjusted if objective negative evidence in the form of cumulative losses is no longer present and additional weight may be given to subjective evidence, such as estimates of future taxable income during carryforward periods and the Company's projections for growth. The Company applies the two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount, which is more than 50% likely of being realized upon ultimate settlement. Income tax positions must meet a more likely than not recognition threshold at the effective date to be recognized upon the adoption of ASC 740 and in subsequent periods. This interpretation also provides guidance on measurement, derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. The following table summarizes the changes to unrecognized tax benefits for the years ended December 31, 2016 , 2015 and 2014 , respectively (in thousands): Years Ended December 31, 2016 2015 2014 Beginning balance of unrecognized tax benefits $ — $ — $ 382 Lapses in the statute of limitations — — (382 ) Ending balance of unrecognized tax benefits $ — $ — $ — At December 31, 2016 and December 31, 2015 , the Company had not accrued any interest or penalties related to uncertain tax positions. The Company does not anticipate that there will be a significant change in the amount of unrecognized tax benefits over the next twelve months. The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. The Company is subject to taxation in the United States and various state and foreign jurisdictions. The Company's Federal and state returns since inception are subject to examination due to the carryover of net operating losses. As of December 31, 2016 , the Company’s tax years from 2011 through 2012 are subject to examination by the United Kingdom tax authorities. The statute of limitations for the assessment and collection of income taxes related to other foreign tax returns varies by country. In the foreign countries where the Company has operations, these time periods generally range from three to five years after the year for which the tax return is due or the tax is assessed.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Leases The Company has lease agreements for its office, manufacturing, warehousing and laboratory space and for office equipment. Rent and operating expenses charged were $1,871,000 , $1,233,000 and $1,147,000 for the years ended December 31, 2016 , 2015 , and 2014 , respectively. Pursuant to the Company’s lease agreements, a portion of the monthly rent has been deferred. The balance deferred at December 31, 2016 and 2015 was $4,097,000 and $1,445,000 , respectively. Annual future minimum obligations for leases as of December 31, 2016 are as follows (in thousands): Years Ending December 31, Amount 2017 $ 1,644 2018 1,792 2019 1,913 2020 1,972 2021 1,372 Thereafter 1,365 Total minimum lease payments $ 10,058 Legal Proceedings From time to time, the Company is party to litigation and other legal proceedings in the ordinary course, and incidental to the conduct of its business. While the results of any litigation or other legal proceedings are uncertain, the Company does not believe the ultimate resolution of any pending legal matters is likely to have a material effect on its financial position or results of operations.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2016
Inventory Disclosure [Abstract]
Inventories	Inventories Inventory on hand as of December 31, 2016 and 2015 comprised the following (in thousands): December 31, 2016 2015 Raw materials $ 2,171 $ 1,147 Work-in-process 1,488 693 Finished goods 2,974 1,214 $ 6,633 $ 3,054

Property and Equipment, net

Property and Equipment, net	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment, Net [Abstract]
Property and Equipment, net	Property and Equipment, net Property and equipment comprised the following as of December 31, 2016 and 2015 (in thousands): December 31, 2016 2015 Property and equipment—at cost: Plant and machinery $ 10,145 $ 7,728 Instruments 9,869 8,195 Office equipment 1,714 1,526 Leasehold improvements 10,100 4,311 Total property and equipment—at cost 31,828 21,760 Less accumulated depreciation (13,560 ) (10,364 ) Property and equipment, net $ 18,268 $ 11,396 Depreciation expense was $3,510,000 , $3,112,000 and $2,429,000 for the years ended December 31, 2016 , 2015 and 2014 , respectively. During the years ended December 31, 2016 , 2015 and 2014 , the Company disposed of certain assets no longer in use with a net book value of $76,000 , $153,000 , and $102,000 , respectively, recorded to cost of revenue, sales and marketing, research and development, or general and administrative expenses based on the asset's respective use.

Loan payable

Loan payable	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Loan payable	Loan payable As of December 31, 2016 and 2015 , long-term debt consisted of the following (in thousands): December 31, 2016 December 31, 2015 Term Loans Term Loan A - 6.9% principal $ 10,000 $ 10,000 Term Loan B - 6.9% principal 10,000 — Final fee obligation 400 400 Unamortized issuance costs (585 ) (883 ) Total debt, net 19,815 9,517 Current portion of long-term debt (7,935 ) 373 Long-term debt $ 11,880 $ 9,890 Term Loans In January 2015, the Company entered into a Loan and Security Agreement, or the LSA, with Solar Capital Partners (as successor-in-interest to General Electric Capital Corporation), and certain other financial institutions party thereto, as lenders, pursuant to which the Company obtained (a) up to $35,000,000 in a series of term loans and (b) a revolving loan in the maximum amount of $5,000,000 . Under the terms of the LSA, the Company may, subject to certain conditions, borrow: • $10,000,000 on or before March 31, 2015, or Term Loan A; • an additional $10,000,000 , or Term Loan B, subject to the Company’s satisfaction of regulatory requirements necessary to CE Mark its ePlex system in Europe by a specified date; and • an additional $15,000,000 , or Term Loan C, and together with Term Loan A and Term Loan B, the Term Loans, subject to the Company’s satisfaction of FDA 510(k) market clearance for the sale of the Company’s ePlex system in the United States by a specified date. The Company borrowed $10,000,000 on each of March 27, 2015 and June 10, 2016 pursuant to Term Loan A and Term Loan B, respectively. The Term Loans will accrue interest at a rate equal to ( a) the greater of 1.00% or the 3-year treasury rate in effect at the time of funding, plus (b) an applicable margin between 4.95% and 5.90% per annum. The Company is only required to make interest payments on amounts borrowed pursuant to the Term Loans from the applicable funding date until March 1, 2017 , or the Interest Only Period. Following the Interest Only Period, monthly installments of principal and interest under the Term Loans will be due until the original principal amount and applicable interest is fully repaid by January 12, 2019 , or the Maturity Date. Interest expense recognized on the Term Loans for the years ended December 31, 2016 and 2015 totaled $1,184,000 and $611,000 , respectively, for the stated interest and final fee accrual. In July 2016, the Company entered into an amendment to the LSA pursuant to which the lenders reallocated certain funding commitments under the LSA between the lenders, and the parties extended the date by which the future funding requirements in respect of Term Loan C must be satisfied. Under the LSA, the Company is required to comply with certain affirmative and negative covenants, including, without limitation, delivering reports and notices relating to the Company’s financial condition and certain regulatory events and intellectual property matters, as well as limiting the creation of liens, the incurrence of indebtedness, and the making of certain investments, payments and acquisitions, other than as specifically permitted by the LSA. As of December 31, 2016 , the Company was in compliance with all covenants under the LSA. Revolving Loan Pursuant to the LSA, the Company may borrow up to $5,000,000 under the revolving loan facility. Borrowings under the revolving loan will accrue interest at a rate equal to (a) the greater of 1.25% per annum or a base rate as determined by a three-month LIBOR-based formula, plus (b) an applicable margin between 2.95% and 3.95% based on certain criteria as set forth in the LSA. All principal and interest outstanding under the revolving loan is due and payable on the Maturity Date. Following the funding of Term Loan A, the Company is required to pay a commitment fee equal to 0.75% per annum of the amounts made available but unborrowed under the revolving loan. As of December 31, 2016 , the Company had not borrowed any amounts pursuant the revolving loan facility. Interest expense recognized for the unused revolving loan facility fee for the years ended December 31, 2016 and 2015 was $42,000 and $34,000 , respectively. Debt Issuance Costs As of December 31, 2016 and December 31, 2015, the Company had $585,000 and $883,000 , respectively, of unamortized debt issuance discount, which is offset against borrowings in long-term and short-term debt. For the twelve months ended December 31, 2016 and 2015 , amortization of debt issuance costs was $298,000 and $208,000 , respectively, which was included in interest expense in the Company's unaudited condensed consolidated statements of comprehensive loss for the periods presented. Letter of Credit In September 2012, the Company provided a $758,000 letter of credit issued by Banc of California to the landlord of its executive office facility in Carlsbad, California. This letter of credit was secured with $758,000 of restricted cash as of December 31, 2016 .

Employee benefit plan

Employee benefit plan	12 Months Ended
	Dec. 31, 2016
Compensation and Retirement Disclosure [Abstract]
Employee benefit plan	Employee benefit plan The Company has a 401(k) tax-deferred savings plan, whereby eligible employees may contribute a percentage of their eligible compensation. The Company may make matching contributions under the 401(k) plan; however, the Company has not made any such contributions to date.

Other current liabilities

Other current liabilities	12 Months Ended
	Dec. 31, 2016
Other Current Assets and Liabilities and Other Noncurrent Liabilities [Abstract]
Other current liabilities	Other current liabilities Other current liabilities as of December 31, 2016 and 2015 consisted of the following (in thousands): December 31, 2016 2015 Accrued royalties $ 949 $ 1,608 Accrued warranties 219 118 Accrued tenant improvements 789 — Deferred revenue 658 267 Other accrued liabilities 1,518 732 Total $ 4,133 $ 2,725

Fair Value of Financial Instrum

Fair Value of Financial Instruments	12 Months Ended
	Dec. 31, 2016
Fair Value Disclosures [Abstract]
Fair value of financial instruments	Fair value of financial instruments The following table presents the financial instruments measured at fair value on a recurring basis on the financial statements of the Company and the valuation approach applied to each class of financial instruments at December 31, 2016 and 2015 , respectively, (in thousands): December 31, 2016 Quotes Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Money market funds (cash equivalents) $ 556 $ — $ — $ 556 Corporate notes and bonds — 18,821 — 18,821 U.S. government and agency securities — 3,503 — 3,503 Commercial paper — 3,283 — 3,283 $ 556 $ 25,607 $ — $ 26,163 December 31, 2015 Quotes Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Money market funds (cash equivalents) $ 22,128 $ — $ — $ 22,128 Corporate notes and bonds — 8,483 — 8,483 U.S. government and agency securities — 799 — 799 Commercial paper — 798 — 798 $ 22,128 $ 10,080 $ — $ 32,208 At December 31, 2016 , the carrying value of the financial instruments measured and classified within Level 1 was based on quoted prices and marked to market. Level 2 inputs for the valuations are limited to quoted prices for similar assets or liabilities in active markets and inputs other than quoted prices that are observable for the asset or liability.

Investments (Notes)

Investments (Notes)	12 Months Ended
	Dec. 31, 2016
Investments, Debt and Equity Securities [Abstract]
Investments	Investments The following table summarizes the Company’s available-for-sale investments at December 31, 2016 (in thousands): Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value Corporate notes and bonds $ 18,846 $ — $ (25 ) $ 18,821 U.S. government and agency securities 3,506 — (3 ) 3,503 Commercial Paper 3,283 — — 3,283 Total $ 25,635 $ — $ (28 ) $ 25,607 During 2013, the Company sold its preferred stock investment in ALL in connection with ALL's acquisition by Illumina, Inc., resulting in a $1,392,000 realized gain. Additionally, in 2016 and 2015 the Company received an additional $9,000 and $223,000 , respectively, related to the release of escrowed proceeds. The following table summarizes the maturities of the Company’s available-for-sale securities at December 31, 2016 (in thousands): Amortized Cost Estimated Fair Value Due in one year or less $ 25,635 $ 25,607 Due after one year through two years — — Total $ 25,635 $ 25,607

Selected Quarterly Financial Da

Selected Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2016
Quarterly Financial Information Disclosure [Abstract]
Quarterly financial data (unaudited)	uarterly financial data (unaudited) Year Ended December 31, 2016 (In thousands, except per share data) First Quarter Second Quarter Third Quarter Fourth Quarter Total revenue $ 11,064 $ 12,512 $ 10,813 $ 14,885 Gross profit $ 6,689 $ 7,792 $ 6,451 $ 8,642 Loss from operations $ (12,708 ) $ (12,588 ) $ (11,627 ) $ (12,058 ) Net loss $ (12,958 ) $ (12,907 ) $ (12,058 ) $ (12,678 ) Per share data: Net loss per common share—basic and diluted $ (0.30 ) $ (0.30 ) $ (0.27 ) $ (0.27 ) Year Ended December 31, 2015 (In thousands, except per share data) First Quarter Second Quarter Third Quarter Fourth Quarter Total revenue $ 10,107 $ 7,646 $ 8,472 $ 13,186 Gross profit $ 6,116 $ 4,360 $ 5,120 $ 8,498 Loss from operations $ (10,027 ) $ (11,930 ) $ (11,117 ) $ (8,461 ) Net loss $ (9,869 ) $ (12,152 ) $ (11,394 ) $ (8,782 ) Per share data: Net loss per common share—basic and diluted $ (0.24 ) $ (0.29 ) $ (0.27 ) $ (0.21 )

Subsequent Evens (Notes)

Subsequent Evens (Notes)	2 Months Ended
	Feb. 28, 2017
Subsequent Event [Line Items]
Subsequent Events [Text Block]	16. Subsequent events The Company has completed an evaluation of all subsequent events through the issuance date of these consolidated financial statements and the following represents subsequent events for disclosure. On February 27, 2017 the Company entered into a second amendment to the LSA with Solar Capital Partners and certain other financial institutions party thereto, as lenders, pursuant to which the parties extended the date by which the future funding requirements in respect of Term Loan C must be satisfied. In addition, the parties agreed to extend the Interest-Only Period in respect of amounts already borrowed under Term Loan A and Term Loan B, and the amount, if any, borrowed pursuant to Term Loan C, until June 1, 2017 . The parties also agreed that the Company has the option to further extend the Interest-Only Period until August 1, 2017 , and subsequently to March 1, 2018 , subject in each case to the satisfaction of certain conditions.

Organization and Basis of Pre23

Organization and Basis of Presentation Reclassification (Policies)	12 Months Ended
	Dec. 31, 2015
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accounting Changes and Error Corrections [Text Block]	he consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

Summary of Significant Accoun24

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Accounting Policies [Abstract]
Organization and basis of presentation	GenMark Diagnostics, Inc., the Company or GenMark, was formed by Osmetech plc, or Osmetech, as a Delaware corporation in February 2010, and had no operations prior to its initial public offering, or the IPO, which was completed in June 2010. Immediately prior to the closing of the IPO, GenMark acquired all of the outstanding ordinary shares of Osmetech in a reorganization, accounted for in a manner similar to a pooling-of-interests, under the applicable laws of the United Kingdom. As a result of the reorganization, all of the issued ordinary shares in Osmetech were cancelled in consideration of (i) the issuance of common stock of GenMark to the former shareholders of Osmetech and (ii) the issuance of new shares in Osmetech to GenMark. Following the reorganization, Osmetech became a subsidiary controlled by GenMark, and the former shareholders of Osmetech received shares of GenMark. Any historical discussion of GenMark relates to Osmetech and its consolidated subsidiaries prior to the reorganization. In September 2012, GenMark placed Osmetech into liquidation to simplify its corporate structure. The liquidation of Osmetech was completed in the fourth quarter of 2013. Segment Reporting The Company currently operates as one operating segment. Operating segments are defined as components of an enterprise for which separate financial information is evaluated regularly by the chief operating decision maker, who is the chief executive officer, in deciding how to allocate resources and assessing performance. The Company’s business operates in one operating segment because the Company’s chief operating decision maker evaluates the Company’s financial information and resources and assesses the performance of these resources on a consolidated basis. Since the Company operates in one operating segment, all required financial segment information can be found in the consolidated financial statements. Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, or U.S. GAAP, requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the notes thereto. The Company’s significant estimates included in the preparation of the financial statements are related to accounts receivable, inventories, property and equipment, intangible assets, employee related compensation accruals, warranty liabilities, tax valuation accounts and stock-based compensation. Actual results could differ from those estimates. Basis of Presentation The accompanying financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net losses from operations since its inception and has an accumulated deficit of $355,270,000 at December 31, 2016 . Management expects operating losses to continue through the foreseeable future. The Company's ability to transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support its cost structure through expanding its product offerings and consequently increasing its product revenues. Cash, cash equivalents, restricted cash, and investments at December 31, 2016 totaled $41,566,000 . The Company has prepared cash flow forecasts which indicate, based on the Company’s current cash resources available, that the Company will have sufficient resources to fund its business for at least the next 12 months from the date of this filing. The accompanying consolidated financial statements have been prepared in accordance with U.S. GAAP and applicable regulations of the Securities and Exchange Commission, or the SEC.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
Cash and Cash Equivalents and Short-Term Investments	Cash and Cash Equivalents and Marketable Securities Cash and cash equivalents consist of cash on deposit with banks, money market instruments and certificates of deposit with original maturities of three months or less at the date of purchase. Marketable securities consist of certificates of deposits that mature in greater than three months . Marketable securities are accounted for as "available-for-sale" with the carrying amounts reported in the balance sheets stated at cost, which approximates their fair market value, with unrealized gains and losses, if any, reported as a separate component of stockholders' equity and included in comprehensive loss.
Restricted Cash	Restricted Cash Restricted cash represents amounts designated for uses other than current operations and includes $758,000 at December 31, 2016 held as security for the Company’s letter of credit with Banc of California.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company uses a fair value hierarchy with three levels of inputs, of which the first two are considered observable and the last unobservable, to measure fair value: • Level 1 — Quoted prices in active markets for identical assets or liabilities. • Level 2 — Inputs, other than Level 1, that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The carrying amounts of financial instruments such as accounts receivable, prepaid expenses and other current assets, accounts payable, and accrued liabilities approximate the related fair values due to the short-term maturities of these instruments.
Receivables	Receivables Accounts receivable consist of amounts due to the Company for sales to customers and are recorded net of an allowance for doubtful accounts. The allowance for doubtful accounts is determined based on an assessment of the collectability of specific customer accounts, the aging of accounts receivable, and a reserve for unknown items based upon the Company’s historical experience.
Inventories	Inventories Inventories are stated at the lower of cost (first-in, first-out) or net realizable value and include direct labor, materials, and manufacturing overhead. The Company periodically reviews inventory for evidence of slow-moving or obsolete parts, and writes inventory down to net realizable value, as needed. This write-down is based on management’s review of inventories on hand, compared to estimated future usage and sales, shelf-life assumptions, and assumptions about the likelihood of obsolescence. If actual market conditions are less favorable than those projected by the Company, additional inventory write-downs may be required. Inventory impairment charges establish a new cost basis for inventory and charges are not reversed subsequently to income, even if circumstances later suggest that increased carrying amounts are recoverable.
Property and Equipment-net	Property and Equipment-net Property, equipment and leasehold improvements are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets, which are: Machinery and laboratory equipment 3 – 5 years Instruments 4 – 5 years Office equipment 3 – 7 years Leasehold improvements over the shorter of the remaining life of the lease or the useful economic life of the asset Property and equipment includes diagnostic instruments used for sales demonstrations or placed with customers under several types of arrangements, including performance evaluation programs, or PEPs, and reagent rental agreements. PEPs are placed with customers for evaluation periods of up to three months and the Company retains title to the instruments under these arrangements.
Intangible Assets	Intangible Assets Intangible assets are comprised of licenses or sublicenses to technology covered by patents owned by third parties, and are amortized on a straight-line basis over the expected useful lives of these assets, which is generally 10 years. Amortization of licenses typically begins upon the Company obtaining access to the licensed technology and is recorded in cost of revenues for licenses supporting commercialized products. The amortization of licenses to technology supporting products in development is recorded in research and development expenses.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company assesses the recoverability of long-lived assets, including intangible assets, by periodically evaluating the carrying value whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If impairment is indicated, the Company writes down the carrying value of the asset to its estimated fair value. This fair value is primarily determined based on estimated discounted cash flows. The Company did not recognize any impairment charges during the years ended December 31, 2016 and 2015.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, or U.S. GAAP, requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the notes thereto. The Company’s significant estimates included in the preparation of the financial statements are related to accounts receivable, inventories, property and equipment, intangible assets, employee related compensation accruals, warranty liabilities, tax valuation accounts and stock-based compensation. Actual results could differ from those estimates.
Segment Reporting	Segment Reporting The Company currently operates as one operating segment. Operating segments are defined as components of an enterprise for which separate financial information is evaluated regularly by the chief operating decision maker, who is the chief executive officer, in deciding how to allocate resources and assessing performance. The Company’s business operates in one operating segment because the Company’s chief operating decision maker evaluates the Company’s financial information and resources and assesses the performance of these resources on a consolidated basis. Since the Company operates in one operating segment, all required financial segment information can be found in the consolidated financial statements.
Revenue Recognition	Revenue Recognition The Company recognizes revenue from product sales and contract arrangements, net of discounts and sales related taxes. The Company recognizes revenue from product sales when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable and collectability is reasonably assured. The Company offers customers the choice to either purchase a system outright or to receive a system free of charge in exchange for an annual minimum purchase commitment for diagnostic test cartridges. When a system is sold, the Company generally recognizes revenue upon shipment of the unit, however, if the end user already has the instrument being purchased installed at its location, revenue is recognized when the revenue recognition terms other than delivery have been satisfied. When a system is placed free of charge under a “reagent rental” agreement, the Company retains title to the equipment and it remains capitalized on the balance sheet under property and equipment. Under reagent rental agreements, the Company’s customers pay an additional system rental fee for each test cartridge purchased which varies based on the monthly volume of test cartridges purchased. The system rental fee and diagnostic test cartridges are recognized as contingent rental payments and are included in product revenue in the Company’s consolidated financial statements. The Company has not had significant product returns and is not contractually obligated to accept returns unless such returns are related to warranty provisions. The Company generally does not accept reagent product returns, mainly due to FDA regulations, and does not offer volume rebates or provide price protection. The Company enters into PEP agreements pursuant to which an instrument is installed on the premises of a pre-qualified customer for the purpose of allowing the customer to evaluate the instrument’s functionality over an extended trial period. The customer is generally required to purchase a minimum quantity of reagents and, at the end of the evaluation period, must purchase or return the instrument or sign a reagent rental agreement. Revenues related to royalties received from licenses are recognized evenly over the contractual period to which the license relates. In those cases where the Company bills shipping and handling costs to customers, the amounts billed are included in product revenue
Product Warranties	Product Warranties The Company generally offers a one -year warranty for its instruments sold to customers and up to a sixty day warranty for reagents and provides for the estimated cost of the product warranty at the time the system sale is recognized. Factors that affect the Company’s warranty reserves include the number of units sold, historical and anticipated rates of warranty repairs and the cost per repair. The Company periodically assesses the adequacy of the warranty reserve and adjusts the amount as necessary. Product warranty reserve activity for the years ended December 31, 2016 , 2015 and 2014 is as follows (in thousands): 2016 2015 2014 Beginning balance $ 118 $ 195 $ 226 Warranty expenses incurred (421 ) (430 ) (608 ) Provisions 522 353 577 Ending balance $ 219 $ 118 $ 195
Research and Development Costs	Research and Development Costs The Company expenses all research and development costs in the periods in which they are incurred unless there is alternative future use that supports the capitalization of an asset.
Income Taxes	Income Taxes Current income tax expense is the amount of income taxes expected to be payable for the current year. A deferred income tax liability or asset is established for the expected future tax consequences resulting from the differences in financial reporting and tax bases of assets and liabilities. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized. A full valuation allowance has been recorded against the Company’s net deferred tax assets due to the uncertainty surrounding the Company’s ability to utilize these assets in the future. The Company provides for uncertain tax positions when such tax positions do not meet the recognition thresholds or measurement standards prescribed by the authoritative guidance on income taxes. Amounts for uncertain tax positions are adjusted in periods when new information becomes available or when positions are effectively settled. The Company recognizes accrued interest related to uncertain tax positions as a component of income tax expense. A tax position that is more likely than not to be realized is measured at the largest amount of tax benefit that is greater than 50% likely of being realized upon settlement with the taxing authority that has full knowledge of all relevant information. Measurement of a tax position that meets the more likely than not threshold considers the amounts and probabilities of the outcomes that could be realized upon settlement using the facts, circumstances and information available at the reporting date.
Share-Based Compensation	Stock-Based Compensation The Company recognizes stock-based compensation expense related to stock options, shares purchased under the Company's ESPP, restricted stock awards, restricted stock units and market-based stock units granted to employees and directors in exchange for services. The compensation expense is based on the fair value of the applicable award utilizing various assumptions regarding the underlying attributes of the award. The stock-based compensation expense is recorded in cost of revenues, sales and marketing, research and development, and/or general and administrative expenses based on the employee's respective function. The estimated fair value of stock granted, net of forfeitures expected to occur during the vesting period, is amortized as compensation expense that approximates straight-line expense to reflect vesting as it occurs. The stock option expense is derived from the Black-Scholes Option Pricing Model that uses several judgment-based variables to calculate the expense. The market-based stock expense is derived from the Monte Carlo Simulation Valuation. The inputs utilized in the valuation of the stock-based awards include the following factors: • Expected Term. Expected term represents the period that the stock-based awards are expected to be outstanding and is determined by using the simplified method. • Expected Volatility . Expected volatility represents the expected volatility in the Company’s stock price over the expected term of the option or market-based award and is determined by review of the Company’s and similar companies’ historical experience. • Expected Dividend . The valuation methods required a single expected dividend yield as an input. The Company assumed no dividends as it has never paid dividends and has no current plans to do so. • Risk-Free Interest Rate. The risk-free interest rate is based on published U.S. Treasury rates in effect at the time of grant for periods corresponding with the expected term of the option or market-based award. The compensation expense related to the grant of restricted stock awards or units is calculated as the fair market value of the stock on the grant date as further adjusted to reflect expected forfeitures.
Foreign Currency Translation	Foreign Currency Translation During 2015, the Company established foreign subsidiaries with currencies other than the U.S. Dollar. The assets and liabilities of the Company's entities outside the U.S. are translated into U.S. Dollars based on the foreign currency exchange rates at the end of each period, while revenues and expenses are translated at weighted average exchange rates during the applicable period. Gains or losses resulting from these foreign currency translations of the Company's assets and liabilities are recorded in accumulated comprehensive loss in the consolidated balance sheets. Foreign currency translation impacts recorded in accumulated other comprehensive loss for the year ended December 31, 2016 and 2015 was $77,000 and $36,000 , respectively. Transactions in foreign currencies were recognized using the rate of exchange prevailing at the date of the transaction. Foreign exchange losses, which are included in the accompanying consolidated statements of operations, totaled $169,000 , $91,000 and $9,000 for the years ended December 31, 2016 , 2015 and 2014 , respectively, and relate primarily to transactions denominated in Euros.
Net Loss per Common Share	Net Loss per Common Share Basic net loss per share is calculated by dividing loss available to stockholders of our common stock (the numerator) by the weighted average number of shares of the Company's common stock outstanding during the period (the denominator). Shares issued during the period and shares reacquired during the period are weighted for the portion of the period that they were outstanding. Diluted loss per share is calculated in a similar way to basic loss per share except that the denominator is increased to include the number of additional shares that would have been outstanding if the dilutive potential shares had been issued unless the effect would be anti-dilutive. The calculations of diluted net loss per share for the years ended December 31, 2016 , 2015 and 2014 did not include the effects of the following stock options or other unvested equity awards which were outstanding as of the end of each year because the inclusion of these securities would have been anti-dilutive (in thousands). Year Ended December 31, 2016 2015 2014 Options outstanding to purchase common stock 2,570 3,004 2,479 Other unvested equity awards 2,000 1,267 948 Total 4,570 4,271 3,427
Concentration of Risk	Concentration of Risk Financial instruments which potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents, short-term investment securities, and accounts receivable. We limit our exposure to credit loss by placing our cash with high credit quality financial institutions. We have established guidelines relative to diversification of our cash and investment securities and their maturities that are intended to secure safety and liquidity. The following table summarizes customers who accounted for 10% or more of net accounts receivable: December 31, 2016 2015 Laboratory Corporation of America, Inc. 33 % 35 %	0.35
Comprehensive Loss	Comprehensive Loss The Company has the option to present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single continuous statement of comprehensive income or in two separate but consecutive statements. The Company’s comprehensive loss comprises net losses, unrealized gains and losses on available for sale securities, and foreign currency translation.
Recent Accounting Pronouncements	From time to time, new accounting pronouncements are issued by the Financial Accounting Standard Board, or the FASB, or other standard setting bodies that the Company adopts as of the specified effective date. The Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. In March 2016, the FASB issued Accounting Standards Update, or ASU, 2016-09, Improvements to Employee Share-Based Payment Accounting. This guidance simplifies how several aspects of share-based payments are accounted for and presented in the financial statements. This guidance is effective for the Company beginning January 1, 2017 and the Company will adopt this ASU in the first quarter of 2017. The Company has excess tax benefits for which a benefit could not be previously recognized of approximately $1,979,000 . Upon adoption, the balance of the unrecognized excess tax benefits will be reversed with the impact recorded to retained earnings, including any change to the valuation allowance as a result of adoption. Due to the full valuation allowance on the Company's U.S. deferred tax assets, the Company does not expect any impact to the financial statements as a result of this adoption. In February 2016, the FASB issued ASU 2016-02, Leases. This ASU outlines a comprehensive lease accounting model and supersedes the current lease guidance. The new guidance requires lessees to recognize lease liabilities and corresponding right-of-use assets for all leases with lease terms of greater than 12 months. It also changes the definition of a lease and expands the disclosure requirements of lease arrangements. The new guidance must be adopted using the modified retrospective approach and will be effective for the Company starting in the first quarter of 2019, with early adoption permitted. The Company is evaluating the effects adoption will have on its consolidated financial statements. The Company expects this adoption will result in a material increase in the assets and liabilities on our consolidated balance sheets and will likely have an immaterial impact on our consolidated statements of comprehensive loss. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, an updated standard on revenue recognition. ASU 2014-09 provides enhancements to the quality and consistency of how revenue is reported by companies while also improving comparability in the financial statements of companies reporting using International Financial Reporting Standards or U.S. GAAP. The main purpose of the new standard is for companies to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration to which a company expects to be entitled in exchange for those goods or services. The new standard also will result in enhanced disclosures of revenue, provide guidance for transactions that were not previously addressed comprehensively, and improve guidance for multiple-element arrangements. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers: Deferral of the Effective Date, which deferred the effective date of the new revenue standard for periods beginning after December 15, 2016 to December l5, 2017, with early adoption permitted but not earlier than the original effective date. Accordingly, the updated standard is effective for the Company in the first quarter of fiscal 2018. The Company is currently evaluating the overall impact this standard will have on our consolidated financial statements, as well as the expected timing and method of adoption. Based on our preliminary assessment, the Company does not anticipate a material impact on its financial statements. The Company is continuing this assessment, which may identify other impacts.

Income Taxes Schedule of Compon

Income Taxes Schedule of Components of Net Income (Policies)	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Schedule of Income (Loss)Foreign and Domestic [Table Text Block]	Years Ended December 31, 2016 2015 2014 Domestic $ (50,651 ) $ (42,221 ) $ (37,766 ) Foreign 150 64 (1,070 ) Worldwide Income (Loss) $ (50,501 ) $ (42,157 ) $ (38,836 )

Summary of Significant Accoun26

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Accounts receivable and the allowance for doubtful accounts	he allowance for doubtful accounts as of December 31, 2016 , is as follows (in thousands): Allowance for doubtful accounts Balance December 31, 2014 $ 2,702 Provision for doubtful accounts 25 Balance December 31, 2015 $ 2,727 Provision for doubtful accounts 13 Balance December 31, 2016 $ 2,740
Estimated useful lives of property and equipment	Property, equipment and leasehold improvements are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets, which are: Machinery and laboratory equipment 3 – 5 years Instruments 4 – 5 years Office equipment 3 – 7 years Leasehold improvements over the shorter of the remaining life of the lease or the useful economic life of the asset
Product warranty reserve activity	Product warranty reserve activity for the years ended December 31, 2016 , 2015 and 2014 is as follows (in thousands): 2016 2015 2014 Beginning balance $ 118 $ 195 $ 226 Warranty expenses incurred (421 ) (430 ) (608 ) Provisions 522 353 577 Ending balance $ 219 $ 118 $ 195
Computations of diluted net loss per share	The calculations of diluted net loss per share for the years ended December 31, 2016 , 2015 and 2014 did not include the effects of the following stock options or other unvested equity awards which were outstanding as of the end of each year because the inclusion of these securities would have been anti-dilutive (in thousands). Year Ended December 31, 2016 2015 2014 Options outstanding to purchase common stock 2,570 3,004 2,479 Other unvested equity awards 2,000 1,267 948 Total 4,570 4,271 3,427
Company sales to individual customers representing greater than 10% of the total	December 31, 2016 2015 Laboratory Corporation of America, Inc. 33 % 35 %

Intangible Assets, net (Tables)

Intangible Assets, net (Tables)	12 Months Ended
	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of intangible assets	Intangible assets as of December 31, 2016 and 2015 consisted of the following (in thousands): December 31, 2016 December 31, 2015 Gross carrying amount Accumulated amortization Net carrying amount Gross carrying amount Accumulated amortization Net carrying amount Licensed intellectual property $ 4,250 $ (1,580 ) $ 2,670 $ 3,550 $ (1,174 ) $ 2,376
Summary of estimated future amortization expense	stimated future amortization expense for these licenses is as follows (in thousands): Years Ending December 31, Future Amortization Expense 2017 $ 497 2018 497 2019 497 2020 497 2021 497 Thereafter 185 Total $ 2,670

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2016
Compensation Related Costs [Abstract]
Schedule of stock option activity	The following table summarizes stock option activity during the year ended December 31, 2016 : Number of shares Weighted average exercise price Outstanding at December 31, 2015 3,004,011 $ 9.74 Granted 5,000 $ 4.70 Exercised (98,941 ) $ 7.20 Forfeitures (340,520 ) $ 11.96 Outstanding at December 31, 2016 2,569,550 $ 9.53 Vested and expected to vest at December 31, 2016 2,490,256 $ 9.45 Exercisable at December 31, 2016 1,937,739 $ 8.75
Fair value of stock options granted	Years Ended December 31, 2016 2015 2014 Expected volatility (%) 51 % 49 % 69 % Expected life (years) 5.90 6.06 6.08 Risk free rate (%) 1.35 % 1.67 % 1.82 % Expected dividend yield (%) — % — % — %
Summary of non-vested restricted share award ("RSA") activity	The Company’s restricted stock activity for the year ended December 31, 2016 was as follows: Restricted Stock Awards Restricted Stock Units Number of shares Weighted Average Grant Date Fair Value Number of shares Weighted Average Grant Date Fair Value Unvested at December 31, 2015 32,837 $ 5.00 934,977 $ 12.66 Granted — $ — 1,580,273 $ 5.80 Vested (32,369 ) $ 4.91 (444,365 ) $ 11.79 Forfeitures (312 ) $ 11.19 (304,762 ) $ 7.65 Unvested at December 31, 2016 156 $ 11.19 1,766,123 $ 7.18
Summary of share-based compensation expense
Summary of ESPP activity	A summary of ESPP activity for the years ended December 31, 2016 and 2015 is as follows (in thousands, except share, and per share data): Year Ended December 31, 2016 2015 Shares issued 138,058 122,245 Weighted average fair value of shares issued $ 6.67 $ 7.22 Employee purchases $ 921 $ 884

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Components of income tax expense (benefit) for continuing operations	The components of income tax expense (benefit) were as follows for the years ended December 31, 2016 , 2015 , and 2014 , respectively (in thousands): Years Ended December 31, 2016 2015 2014 Current expense: U.S. federal $ (10 ) $ — $ — State 31 25 (573 ) Foreign (non-U.S. entities) 70 20 — Total current expense (benefit) $ 91 $ 45 $ (573 ) Deferred expense (benefit): U.S. Federal $ 4 $ — $ — State 1 — — Total deferred expense (benefit) $ 5 $ — $ —
Net deferred income taxes	The components of net deferred income taxes consisted of the following at December 31, 2016 and 2015 , respectively (in thousands): As of December 31, 2016 2015 Deferred income tax assets: NOL and credit carryforwards $ 74,375 $ 59,907 Compensation accruals 4,660 3,952 Accruals and reserves 3,437 2,201 State tax provision 8 8 Inventory adjustments 996 559 Intangible assets 645 361 Other 144 5 Subtotal: deferred tax assets 84,265 66,993 Valuation allowance (82,481 ) (66,211 ) Total deferred tax assets 1,784 782 Deferred income tax liabilities: Depreciation (1,784 ) (782 ) Subtotal: deferred tax liabilities (1,784 ) (782 ) Net deferred tax assets $ — $ —
Reconciliation of income tax (expense)	A reconciliation of income tax expense to the amount computed by applying the statutory federal income tax rate to the loss from operations is summarized for the years ended December 31, 2016 , 2015 , and 2014 , respectively, as follows: Years Ended December 31, 2016 2015 2014 U.S. Federal statutory income tax rate 34.0 % 34.0 % 34.0 % Permanent differences (0.3 )% (0.1 )% (0.3 )% State taxes 2.3 % 2.4 % 2.6 % Executive compensation limitation (0.1 )% (0.8 )% (0.7 )% Stock-based compensation (3.5 )% (1.4 )% (1.5 )% Other (0.4 )% 2.1 % 0.3 % Valuation allowance (32.2 )% (36.9 )% (32.9 )% Total tax provision (0.2 )% (0.7 )% 1.5 %
Unrecognized Tax Benefits	The following table summarizes the changes to unrecognized tax benefits for the years ended December 31, 2016 , 2015 and 2014 , respectively (in thousands): Years Ended December 31, 2016 2015 2014 Beginning balance of unrecognized tax benefits $ — $ — $ 382 Lapses in the statute of limitations — — (382 ) Ending balance of unrecognized tax benefits $ — $ — $ —

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Annual future minimum obligations for operating leases	Annual future minimum obligations for leases as of December 31, 2016 are as follows (in thousands): Years Ending December 31, Amount 2017 $ 1,644 2018 1,792 2019 1,913 2020 1,972 2021 1,372 Thereafter 1,365 Total minimum lease payments $ 10,058

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2016
Inventory Disclosure [Abstract]
Summary of inventory on hand	Inventory on hand as of December 31, 2016 and 2015 comprised the following (in thousands): December 31, 2016 2015 Raw materials $ 2,171 $ 1,147 Work-in-process 1,488 693 Finished goods 2,974 1,214 $ 6,633 $ 3,054

Property and Equipment, net (Ta

Property and Equipment, net (Tables)	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment, Net [Abstract]
Property and equipment, net	Property and equipment comprised the following as of December 31, 2016 and 2015 (in thousands): December 31, 2016 2015 Property and equipment—at cost: Plant and machinery $ 10,145 $ 7,728 Instruments 9,869 8,195 Office equipment 1,714 1,526 Leasehold improvements 10,100 4,311 Total property and equipment—at cost 31,828 21,760 Less accumulated depreciation (13,560 ) (10,364 ) Property and equipment, net $ 18,268 $ 11,396

Loan payable Outstanding Debt (

Loan payable Outstanding Debt (Tables)	12 Months Ended
	Dec. 31, 2016
Debt Instrument [Line Items]
Schedule of Long-term Debt Instruments [Table Text Block]	December 31, 2016 December 31, 2015 Term Loans Term Loan A - 6.9% principal $ 10,000 $ 10,000 Term Loan B - 6.9% principal 10,000 — Final fee obligation 400 400 Unamortized issuance costs (585 ) (883 ) Total debt, net 19,815 9,517 Current portion of long-term debt (7,935 ) 373 Long-term debt $ 11,880 $ 9,890

Other current liabilities (Tabl

Other current liabilities (Tables)	12 Months Ended
	Dec. 31, 2016
Other Current Assets and Liabilities and Other Noncurrent Liabilities [Abstract]
Other current liabilities	Other current liabilities as of December 31, 2016 and 2015 consisted of the following (in thousands): December 31, 2016 2015 Accrued royalties $ 949 $ 1,608 Accrued warranties 219 118 Accrued tenant improvements 789 — Deferred revenue 658 267 Other accrued liabilities 1,518 732 Total $ 4,133 $ 2,725

Fair Value of Financial Instr35

Fair Value of Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2016
Fair Value Disclosures [Abstract]
Assets measured at fair value on a recurring basis	The following table presents the financial instruments measured at fair value on a recurring basis on the financial statements of the Company and the valuation approach applied to each class of financial instruments at December 31, 2016 and 2015 , respectively, (in thousands): December 31, 2016 Quotes Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Money market funds (cash equivalents) $ 556 $ — $ — $ 556 Corporate notes and bonds — 18,821 — 18,821 U.S. government and agency securities — 3,503 — 3,503 Commercial paper — 3,283 — 3,283 $ 556 $ 25,607 $ — $ 26,163 December 31, 2015 Quotes Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Money market funds (cash equivalents) $ 22,128 $ — $ — $ 22,128 Corporate notes and bonds — 8,483 — 8,483 U.S. government and agency securities — 799 — 799 Commercial paper — 798 — 798 $ 22,128 $ 10,080 $ — $ 32,208

Investments (Tables)

Investments (Tables)	12 Months Ended
	Dec. 31, 2016
Investments, Debt and Equity Securities [Abstract]
Summary of available-for-sale investments	The following table summarizes the Company’s available-for-sale investments at December 31, 2016 (in thousands): Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value Corporate notes and bonds $ 18,846 $ — $ (25 ) $ 18,821 U.S. government and agency securities 3,506 — (3 ) 3,503 Commercial Paper 3,283 — — 3,283 Total $ 25,635 $ — $ (28 ) $ 25,607
Summary of the maturities of available-for-sale securities	The following table summarizes the maturities of the Company’s available-for-sale securities at December 31, 2016 (in thousands): Amortized Cost Estimated Fair Value Due in one year or less $ 25,635 $ 25,607 Due after one year through two years — — Total $ 25,635 $ 25,607

Selected Quarterly Financial 37

Selected Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2016
Quarterly Financial Information Disclosure [Abstract]
Selected Quarterly Financial Data	Year Ended December 31, 2016 (In thousands, except per share data) First Quarter Second Quarter Third Quarter Fourth Quarter Total revenue $ 11,064 $ 12,512 $ 10,813 $ 14,885 Gross profit $ 6,689 $ 7,792 $ 6,451 $ 8,642 Loss from operations $ (12,708 ) $ (12,588 ) $ (11,627 ) $ (12,058 ) Net loss $ (12,958 ) $ (12,907 ) $ (12,058 ) $ (12,678 ) Per share data: Net loss per common share—basic and diluted $ (0.30 ) $ (0.30 ) $ (0.27 ) $ (0.27 ) Year Ended December 31, 2015 (In thousands, except per share data) First Quarter Second Quarter Third Quarter Fourth Quarter Total revenue $ 10,107 $ 7,646 $ 8,472 $ 13,186 Gross profit $ 6,116 $ 4,360 $ 5,120 $ 8,498 Loss from operations $ (10,027 ) $ (11,930 ) $ (11,117 ) $ (8,461 ) Net loss $ (9,869 ) $ (12,152 ) $ (11,394 ) $ (8,782 ) Per share data: Net loss per common share—basic and diluted $ (0.24 ) $ (0.29 ) $ (0.27 ) $ (0.21 )

Organization and Basis of Pre38

Organization and Basis of Presentation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and cash equivalents	$ 41,566
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Segment Reporting, Disclosure of Major Customers	0.27	0.17	no single customer
Accumulated deficit	$ (355,270)	$ (304,669)

Summary of Significant Accoun39

Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Allowance for Doubtful Accounts Receivable [Roll Forward]
Beginning balance	$ 2,727	$ 2,702
Provision for doubtful accounts	13	25	$ 0
Ending balance		2,727	$ 2,702
Natural Molecular Testing Corporation [Member]
Allowance for Doubtful Accounts Receivable [Roll Forward]
Beginning balance	2,702
Ending balance	$ 2,740	$ 2,702

Summary of Significant Accoun40

Summary of Significant Accounting Policies (Details 1)	12 Months Ended
	Dec. 31, 2016
Maximum [Member]
Estimated useful lives of Property, equipment and leasehold improvements
Expected useful lives of these assets	10 years
Machinery and laboratory equipment [Member] | Maximum [Member]
Estimated useful lives of Property, equipment and leasehold improvements
Expected useful lives of these assets	5 years
Machinery and laboratory equipment [Member] | Minimum [Member]
Estimated useful lives of Property, equipment and leasehold improvements
Expected useful lives of these assets	3 years
Instruments [Member] | Maximum [Member]
Estimated useful lives of Property, equipment and leasehold improvements
Expected useful lives of these assets	5 years
Instruments [Member] | Minimum [Member]
Estimated useful lives of Property, equipment and leasehold improvements
Expected useful lives of these assets	4 years
Office equipment [Member] | Maximum [Member]
Estimated useful lives of Property, equipment and leasehold improvements
Expected useful lives of these assets	7 years
Office equipment [Member] | Minimum [Member]
Estimated useful lives of Property, equipment and leasehold improvements
Expected useful lives of these assets	3 years
Leasehold improvements [Member]
Estimated useful lives of Property, equipment and leasehold improvements
Leasehold improvements	over the shorter of the remaining life of the lease or the useful economic life of the asset

Summary of Significant Accoun41

Summary of Significant Accounting Policies (Details 2) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Product warranty reserve activity
Beginning balance	$ 118	$ 195	$ 226
Warranty expenses incurred	(421)	(430)	(608)
Provisions	522	353	577
Ending balance	$ 219	$ 118	$ 195

Summary of Significant Accoun42

Summary of Significant Accounting Policies (Details 3) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Computations of diluted net loss per share
Anti-dilutive securities excluded from computation of earnings per share amount	4,570	4,271	3,427
Share options [Member]
Computations of diluted net loss per share
Anti-dilutive securities excluded from computation of earnings per share amount	2,570	3,004	2,479
Restricted stock-unvested [Member]
Computations of diluted net loss per share
Anti-dilutive securities excluded from computation of earnings per share amount	2,000	1,267	948

Summary of Significant Accoun43

Summary of Significant Accounting Policies (Details 4)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Concentration Risk [Line Items]
Segment Reporting, Disclosure of Major Customers	0.27	0.17	no single customer
Concentration Risk, Customer	0.33
Company sales to individual customers representing greater than 10% of the total
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Risk Financial instruments which potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents, short-term investment securities, and accounts receivable. We limit our exposure to credit loss by placing our cash with high credit quality financial institutions. We have established guidelines relative to diversification of our cash and investment securities and their maturities that are intended to secure safety and liquidity. The following table summarizes customers who accounted for 10% or more of net accounts receivable: December 31, 2016 2015 Laboratory Corporation of America, Inc. 33 % 35 %	0.35

Summary of Significant Accoun44

Summary of Significant Accounting Policies (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Gain (Loss) on Sale of Equity Investments	$ 9,000	$ 223,000	$ 0
Segment Reporting, Disclosure of Major Customers	0.27	0.17	no single customer
Temporary Equity, Foreign Currency Translation Adjustments	$ 77,000	$ 36,000
Summary of Significant Accounting Policies (Textual) [Abstract]
Impairment charge included in depreciation expense	$ 76,000	153,000	$ 102,000
Summary of Significant Accounting Policies (Additional Textual) [Abstract]
Minimum maturity for cash and cash equivalents at the date of purchase	3 months
Maximum maturity for cash and cash equivalents at the date of purchase	3 months
Periods of performance evaluation period programs (PEPs)	3 months
Restricted cash	$ 758,000	758,000
Impairment charges	0	0	0
Foreign exchange gain (loss)	$ 169,000	$ 91,000	$ 9,000
Concentration Risk, Customer	0.33
Systems [Member]
Summary of Significant Accounting Policies (Textual) [Abstract]
Products warranty period	1 year
Reagents [Member]
Summary of Significant Accounting Policies (Textual) [Abstract]
Products warranty period	60 days
Maximum [Member]
Summary of Significant Accounting Policies (Textual) [Abstract]
Expected useful lives of these assets	10 years
Minimum [Member]
Summary of Significant Accounting Policies (Textual) [Abstract]
Income tax benefit	50.00%
Instruments [Member] | Maximum [Member]
Summary of Significant Accounting Policies (Textual) [Abstract]
Expected useful lives of these assets	5 years
Instruments [Member] | Minimum [Member]
Summary of Significant Accounting Policies (Textual) [Abstract]
Expected useful lives of these assets	4 years
Office equipment [Member] | Maximum [Member]
Summary of Significant Accounting Policies (Textual) [Abstract]
Expected useful lives of these assets	7 years
Office equipment [Member] | Minimum [Member]
Summary of Significant Accounting Policies (Textual) [Abstract]
Expected useful lives of these assets	3 years

Intangible Assets, net (Details

Intangible Assets, net (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Summary of intangible assets
Net carrying amount	$ 2,670
Licensed intellectual property [Member]
Summary of intangible assets
Gross carrying amount	4,250	$ 3,550
Accumulated amortization	(1,580)	(1,174)
Net carrying amount	$ 2,670	$ 2,376

Intangible Assets, net (Detai46

Intangible Assets, net (Details 1) $ in Thousands	Dec. 31, 2016USD ($)
Summary of estimated future amortization expense
2,015	$ 497
2,016	497
2,017	497
2,018	497
2,019	497
Thereafter	185
Net carrying amount	$ 2,670

Intangible Assets, net (Detai47

Intangible Assets, net (Details Textual) - USD ($)	1 Months Ended						3 Months Ended	12 Months Ended
	Aug. 31, 2015	Mar. 31, 2014	Aug. 31, 2013	Mar. 31, 2013	Jul. 31, 2012	Mar. 31, 2012	Jun. 30, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Indefinite-lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period								5 years 4 months 24 days
Amortization expense for intangible assets								$ 406,000	$ 294,000	$ 227,000
Caliper Life Sciences Inc [Member]
Indefinite-lived Intangible Assets [Line Items]
License agreement payments	$ 800,000	$ 550,000		$ 450,000		$ 400,000
Advanced Liquid Logic, Inc. [Member] | Collaborative Arrangement [Member]
Indefinite-lived Intangible Assets [Line Items]
License agreement payments			$ 200,000		$ 250,000		$ 700,000			$ 350,000
Potential additional milestone payments					$ 1,750,000

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($) shares in Millions	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Class of Stock [Line Items]
Shares of stock issued in public follow-on stock offering		3
Proceeds from issuance of common stock			$ 30,920,000	$ 884,000	$ 812,000
TotalIssuanceCosts [Member]
Class of Stock [Line Items]
Fees and Commissions	$ 1,143,000
CommissionFee [Member]
Class of Stock [Line Items]
Fees and Commissions	900,000
CommissionPercentage			3.00%
OtherOfferingFees [Member]
Class of Stock [Line Items]
Fees and Commissions	$ 243,000

Stockholders' Equity Offering (

Stockholders' Equity Offering (Details) - USD ($) $ / shares in Units, shares in Millions	3 Months Ended	7 Months Ended	9 Months Ended
	Sep. 30, 2016	Dec. 31, 2016	Sep. 30, 2016
Equity Offering [Line Items]
MaximumATMOffering		$ 30,000,000
Issuance of common stock, net of offering expenses, Shares			3
Sale of Stock, Price Per Share	$ 9.04		$ 9.04
Stock Issued During Period, Value, New Issues			$ 30,000,000
TotalIssuanceCosts [Member]
Equity Offering [Line Items]
Fees and Commissions	$ 1,143,000
CommissionFee [Member]
Equity Offering [Line Items]
Fees and Commissions	900,000
CommissionPercentage		3.00%
OtherOfferingFees [Member]
Equity Offering [Line Items]
Fees and Commissions	$ 243,000

Stock-Based Compensation (Detai

Stock-Based Compensation (Details)	12 Months Ended
	Dec. 31, 2016$ / sharesshares
Compensation Related Costs [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | shares	2,490,256
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | $ / shares	$ 9.45
Schedule of stock option activity
Number of Share options Outstanding, Beginning Balance | shares	3,004,011
Number of Share options, Granted | shares	5,000
Number of Share options, Exercised | shares	(98,941)
Number of Share options, Cancelled | shares	(340,520)
Number of Share options Outstanding, Ending Balance | shares	2,569,550
Number of Share options, Exercisable | shares	1,937,739
Weighted average exercise price Outstanding, Beginning Balance | $ / shares	$ 9.74
Weighted average exercise price, Granted | $ / shares	4.70
Weighted average exercise price, Exercised | $ / shares	7.20
Weighted average exercise price, Cancelled | $ / shares	11.96
Weighted average exercise price Outstanding, Ending Balance | $ / shares	9.53
Weighted average exercise price, Exercisable | $ / shares	$ 8.75

Stock-Based Compensation (Det51

Stock-Based Compensation (Details1)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Fair value of stock options granted
Expected volatility (%)	51.00%	49.00%	69.00%
Expected life (years)	5 years 10 months 25 days	6 years 22 days	6 years 29 days
Risk free rate (%)	1.35%	1.67%	1.82%
Expected dividend yield (%)	0.00%	0.00%	0.00%

Stock-Based Compensation (Det52

Stock-Based Compensation (Details 2)	12 Months Ended
	Dec. 31, 2016$ / sharesshares
Restricted Stock Awards [Member]
Summary of non-vested restricted share award ("RSA") activity
Non-vested, Number of shares, Beginning balance | shares	32,837
Number of shares, Vested | shares	(32,369)
Number of shares, Cancelled or expired | shares	(312)
Non-vested, Number of shares, Ending balance | shares	156
Non-vested, Weighted average Grant Date Fair Value, Beginning balance	$ 5
Weighted average Grant Date Fair Value, Granted	0
Weighted average Grant Date Fair Value, Vested	4.91
Weighted average Grant Date Fair Value, Cancelled or expired	11.19
Non-vested, Weighted average Grant Date Fair Value, Ending balance	$ 11.19
Restricted Stock Units [Member]
Summary of non-vested restricted share award ("RSA") activity
Non-vested, Number of shares, Beginning balance | shares	934,977
Number of shares, Vested | shares	(444,365)
Number of shares, Cancelled or expired | shares	(304,762)
Non-vested, Number of shares, Ending balance | shares	1,766,123
Non-vested, Weighted average Grant Date Fair Value, Beginning balance	$ 12.66
Weighted average Grant Date Fair Value, Granted	5.80
Weighted average Grant Date Fair Value, Vested	11.79
Weighted average Grant Date Fair Value, Cancelled or expired	7.65
Non-vested, Weighted average Grant Date Fair Value, Ending balance	$ 7.18

Stock-Based Compensation (Det53

Stock-Based Compensation (Details 3) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	$ 9,236	$ 9,995	$ 5,796
Cost of Sales [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	258	209	73
Sales [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	2,329	3,050	1,848
Research and Development Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	2,482	2,498	1,194
General and Administrative Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	$ 4,167	$ 4,238	$ 2,681

Stock-Based Compensation (Det54

Stock-Based Compensation (Details 4) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued			89,000
Weighted average fair value of shares issued	$ 2.27	$ 6.02	$ 7.45
Employee purchases	$ 921		$ 812
Market Share Unit [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value	$ 9.81	18.07
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value	8.01
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	4.94
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value	$ 7.34	$ 18.07
Employee Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued	138,058	122,245
Weighted average fair value of shares issued	$ 6.7	$ 7.2
Employee purchases	$ 921	$ 884

Stock-Based Compensation (Det55

Stock-Based Compensation (Details Textual) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Mar. 31, 2015
Share-based compensation (Textual) [Abstract]
Vesting period		10 years
Future grant of awards under the Plan		79,455
Weighted average fair value of shares issued		$ 2.27	$ 6.02	$ 7.45
Weighted average contractual term of options exercisable		5 years 7 months 30 days
Aggregate intrinsic value of options exercisable		$ 7,036,000
Aggregate intrinsic value of options exercised		$ 896,000	$ 938,000	$ 584,000
Options exercised		98,941
Options outstanding		2,569,550	3,004,011
Options outstanding, weighted average remaining contractual term		6 years 2 months 12 days
Option intrinsic value		$ 7,532,000
Unrecognized compensation cost		$ 3,323,000
Weighted average-period, cost is expected to be recognized		1 year 6 months 25 days
Maximum MSU Payout Percentage		200.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate		51.00%	49.00%	69.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate		1.35%	1.67%	1.82%
Capitalized share-based compensation		$ 0	$ 0	$ 0
Unrecognized tax benefit related to share-based compensation		0	0	0
Restricted Stock Awards [Member]
Share-based compensation (Textual) [Abstract]
Unrecognized compensation cost		$ 1,000
Weighted average-period, cost is expected to be recognized		16 days
Total fair value of restricted stock vested		$ 190,000	580,000	3,466,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period		0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value		$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period		32,369
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period		312
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value		$ 4.91
Restricted Stock Units [Member]
Share-based compensation (Textual) [Abstract]
Unrecognized compensation cost		$ 8,509,000
Weighted average-period, cost is expected to be recognized		2 years 9 months 20 days
Total fair value of restricted stock vested		$ 3,192,000	4,457,000	2,121,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period		1,580,273
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value		$ 5.80
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period		444,365
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period		304,762
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value		$ 11.79
Market Share Unit [Member]
Share-based compensation (Textual) [Abstract]
Unrecognized compensation cost		$ 781,000
Weighted average-period, cost is expected to be recognized	1 year 8 months 30 days
Total fair value of restricted stock vested		$ 2,433,000	$ 29,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period		335,253
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value		$ 4.94
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate		49.00%	45.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate		0.90%	1.10%
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period		192,941
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period		56,269
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value		$ 8.01
Performance Shares [Member]
Share-based compensation (Textual) [Abstract]
Unrecognized compensation cost		$ 133,000
Total fair value of restricted stock vested				$ 147,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period			43,200
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period				10,800
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period			10,800
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value			$ 12.30
Employee Stock [Member]
Share-based compensation (Textual) [Abstract]
Future grant of awards under the Plan		267,839
Weighted average fair value of shares issued		$ 6.7	$ 7.2
2010 Equity Incentive Plan [Member] | Minimum [Member]
Share-based compensation (Textual) [Abstract]
Vesting period		1 year
2010 Equity Incentive Plan [Member] | Maximum [Member]
Share-based compensation (Textual) [Abstract]
Vesting period		4 years
2013 ESPP [Member] | Employee Stock [Member]
Share-based compensation (Textual) [Abstract]
Common stock reserved for future issuance					650,000
Purchase price of common stock as a percentage of fair value		85.00%
Offering period		6 months
Maximum employee investment as a percentage of gross compensation		10.00%
Maximum number of shares per employee		1,500
2013 ESPP [Member] | Employee Stock [Member] | Maximum [Member]
Share-based compensation (Textual) [Abstract]
Offering period		27 months

Stock-Based Compensation Detail

Stock-Based Compensation Details 5 (Details) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	51.00%	49.00%	69.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	1.35%	1.67%	1.82%
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	0.00%	0.00%	0.00%
Market Share Unit [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	49.00%	45.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	0.90%	1.10%
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	222,773	136,730
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	335,253
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 4.94
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period	(192,941)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value	$ 8.01
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period	(56,269)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value	$ 9.81	$ 18.07

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Current expense:
U.S. provision	$ (10)	$ 0	$ 0
State	31	25	(573)
Foreign (non-U.S. entities)	70	20	0
Total current expense	91	45	(573)
Deferred Income Tax Expense (Benefit)	4	0	0
Deferred State and Local Income Tax Expense (Benefit)	1	0	0
Deferred Income Tax Expense (Benefit)	$ 5	$ 0	$ 0

Income Taxes (Details 1)

Income Taxes (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Schedule of Income (Loss)Foreign and Domestic [Line Items]
Income (Loss) from Continuing Operations before Income Taxes, Domestic	$ (50,651)	$ (42,221)	$ (37,766)
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest	(50,501)	(42,157)	(38,836)
Income (Loss) from Continuing Operations before Income Taxes, Foreign	150	64	$ (1,070)
Deferred income tax assets (liabilities):
NOL and credit carryforwards	74,375	59,907
Compensation accruals	4,660	3,952
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals	3,437	2,201
State tax provision	8	8
Inventory adjustments	996	559
Intangible Assets	645	361
Deferred Tax Assets, Other	144	5
Subtotal: Deferred Tax Assets	84,265	66,993
Depreciation	(1,784)	(782)
Deferred Tax Liabilities, Net	(1,784)	(782)
Valuation allowance	(82,481)	(66,211)
Deferred Tax Assets, Net	1,784	782
Net deferred income taxes	$ 0	$ 0

Income Taxes (Details 2)

Income Taxes (Details 2)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Reconciliation of income tax (expense)
U.S. Federal statutory income tax rate	34.00%	34.00%	34.00%
Permanent differences	(0.30%)	(0.10%)	(0.30%)
State taxes	2.30%	2.40%	2.60%
Executive compensation limitation	(0.10%)	(0.80%)	(0.70%)
Stock-based compensation	(3.50%)	(1.40%)	(1.50%)
Other	(0.40%)	2.10%	0.30%
Valuation allowance	(32.20%)	(36.90%)	(32.90%)
Total tax provision	(0.20%)	(0.70%)	1.50%

Income Taxes (Details Textual)

Income Taxes (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Taxes (Textual) [Abstract]
Net operating loss carryforwards related to excess tax benefits from share-based compensation	$ 5,400
Unrecognized Tax Benefits	$ 0	$ 0	$ 0	$ 382
Income Taxes (Additional Textual) [Abstract]
Changes in ownership	stockholders that hold 5% or more of the Company’s common stock
Valuation allowance	$ 82,481	66,211
Probability of realization of income tax upon settlement	50.00%
Domestic (U.S. Entities)
Income Taxes (Textual) [Abstract]
Net operating loss (NOL)	$ 206,900
State and Local Jurisdiction [Member]
Income Taxes (Textual) [Abstract]
Net operating loss (NOL)	$ 165,000
Foreign (non U.S. Entities)
Income Taxes (Textual) [Abstract]
Net operating loss (NOL)		$ 0

Income Taxes (Unrecognized Tax

Income Taxes (Unrecognized Tax Benefit) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Unrecognized Tax Benefits	$ 0	$ 0	$ 382
Lapses in the statute of limitations	0	0	(382)
Unrecognized Tax Benefits	$ 0	$ 0	$ 0

Commitments and Contingencies62

Commitments and Contingencies (Details) $ in Thousands	Dec. 31, 2016USD ($)
Annual future minimum obligations for operating leases
2,015	$ 1,644
2,016	1,792
2,017	1,913
2,018	1,972
2,019	1,372
Thereafter	1,365
Total minimum lease payments	$ 10,058

Commitments and Contingencies63

Commitments and Contingencies (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Rent and operating expenses	$ 1,871	$ 1,233	$ 1,147
Deferred balance	$ 4,097	$ 1,445

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Summary of inventory on hand
Raw materials	$ 2,171	$ 1,147
Work-in-process	1,488	693
Finished goods	2,974	1,214
Total inventory	$ 6,633	$ 3,054

Property and Equipment, net (De

Property and Equipment, net (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Property and equipment-at cost:
Total property and equipment-at cost	$ 31,828	$ 21,760
Less accumulated depreciation	(13,560)	(10,364)
Net property and equipment	18,268	11,396
Plant and machinery [Member]
Property and equipment-at cost:
Total property and equipment-at cost	10,145	7,728
Instruments [Member]
Property and equipment-at cost:
Total property and equipment-at cost	9,869	8,195
Office equipment [Member]
Property and equipment-at cost:
Total property and equipment-at cost	1,714	1,526
Leasehold improvements [Member]
Property and equipment-at cost:
Total property and equipment-at cost	$ 10,100	$ 4,311

Property and Equipment, net (66

Property and Equipment, net (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Property and Equipment, net (Textual) [Abstract]
Depreciation expense	$ 3,510,000	$ 3,112,000	$ 2,429,000
Property, Plant and Equipment [Line Items]
Impairment charge included in depreciation expense	$ 76,000	$ 153,000	$ 102,000

Loan payable (Details)

Loan payable (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Line of Credit Facility [Line Items]
Line of Credit Facility, Interest Rate Description	(a) the greater of 1.25% per annum or a base rate as determined by a three-month LIBOR-based formula, plus (b) an applicable margin between 2.95% and 3.95%
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.75%
Debt Instrument, Unused Borrowing Capacity, Fee	$ 42,000	$ 34,000
Interest Expense, Long-term Debt	1,184,000	611,000
Loan Payable and Line of Credit (Textual) [Abstract]
Restricted cash	$ 758,000	758,000
Debt Instrument, Interest Rate Terms	a) the greater of 1.00% or the 3-year treasury rate in effect at the time of funding, plus (b) an applicable margin between 4.95% and 5.90% per annum.
Debt Interest only Period End	Mar. 1, 2017
Debt Instrument, Maturity Date	Jan. 12, 2019
Unamortized Loan Commitment and Origination Fees and Unamortized Discounts or Premiums	$ 585,000	883,000
Amortization of Financing Costs	298,000	208,000
Term Loan A [Member]
Line of Credit Facility [Line Items]
Loans Payable	10,000,000	$ 10,000,000
Term Loans [Member]
Line of Credit Facility [Line Items]
Loans Payable	35,000,000
Term Loan B [Member]
Line of Credit Facility [Line Items]
Loans Payable	10,000,000
Term Loan C [Member]
Line of Credit Facility [Line Items]
Loans Payable	15,000,000
Letter of Credit [Member] | Banc of California [Member] | Previous Letter Of Credit [Member]
Loan Payable and Line of Credit (Textual) [Abstract]
Restricted Cash and Cash Equivalents, Current	$ 758,000

Loan payable Outstanding Loan B

Loan payable Outstanding Loan Balance (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Line of Credit Facility [Line Items]
Debt Instrument, Unused Borrowing Capacity, Fee	$ 42,000	$ 34,000
Interest Expense, Long-term Debt	1,184,000	611,000
Debt Instrument, Unamortized Discount (Premium), Net	(585,000)	(883,000)
Long-term Debt	19,815,000	9,517,000
Long-term Debt, Current Maturities	(7,935,000)	373,000
Long-term Debt, Excluding Current Maturities	11,880,000	9,890,000
Line of Credit Facility, Maximum Borrowing Capacity	5,000,000
Term Loan A [Member]
Line of Credit Facility [Line Items]
Loans Payable	10,000,000	10,000,000
Term Loan B [Member] [Member]
Line of Credit Facility [Line Items]
Loans Payable	10,000,000	0
Final Fee [Member]
Line of Credit Facility [Line Items]
Loans Payable	$ 400,000	$ 400,000

Other current liabilities (Deta

Other current liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Other current liabilities
Accrued warranties	$ 219	$ 118
Accrued Liabilities	789	0
Deferred Revenue	658	267
Other Accrued Liabilities, Current	1,518	732
Accrued royalties	949	1,608
Total	$ 4,133	$ 2,725

Fair Value of Financial Instr70

Fair Value of Financial Instruments (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Gain (Loss) on Sale of Equity Investments	$ 9	$ 223	$ 0
U.S. Government and Agency Securities [Member] | Quotes Prices in Active Markets for Identical Assets (Level 1) [Member]
Assets measured at fair value on a recurring basis
Financial assets	0
Fair Value, Measurements, Recurring [Member]
Assets measured at fair value on a recurring basis
Financial assets	26,163	32,208
Fair Value, Measurements, Recurring [Member] | Quotes Prices in Active Markets for Identical Assets (Level 1) [Member]
Assets measured at fair value on a recurring basis
Financial assets	556	22,128
Fair Value, Measurements, Recurring [Member] | Significant Other Observable Inputs (Level 2) [Member]
Assets measured at fair value on a recurring basis
Financial assets	25,607	10,080
Fair Value, Measurements, Recurring [Member] | Significant Unobservable Inputs (Level 3) [Member]
Assets measured at fair value on a recurring basis
Financial assets	0	0
Fair Value, Measurements, Recurring [Member] | Money Market Funds [Member]
Assets measured at fair value on a recurring basis
Financial assets	556	22,128
Fair Value, Measurements, Recurring [Member] | Money Market Funds [Member] | Quotes Prices in Active Markets for Identical Assets (Level 1) [Member]
Assets measured at fair value on a recurring basis
Financial assets	556	22,128
Fair Value, Measurements, Recurring [Member] | Money Market Funds [Member] | Significant Other Observable Inputs (Level 2) [Member]
Assets measured at fair value on a recurring basis
Financial assets	0	0
Fair Value, Measurements, Recurring [Member] | Money Market Funds [Member] | Significant Unobservable Inputs (Level 3) [Member]
Assets measured at fair value on a recurring basis
Financial assets	0	0
Fair Value, Measurements, Recurring [Member] | Corporate Notes and Bonds [Member]
Assets measured at fair value on a recurring basis
Financial assets	18,821	8,483
Fair Value, Measurements, Recurring [Member] | Corporate Notes and Bonds [Member] | Quotes Prices in Active Markets for Identical Assets (Level 1) [Member]
Assets measured at fair value on a recurring basis
Financial assets	0
Fair Value, Measurements, Recurring [Member] | Corporate Notes and Bonds [Member] | Significant Other Observable Inputs (Level 2) [Member]
Assets measured at fair value on a recurring basis
Financial assets	18,821	8,483
Fair Value, Measurements, Recurring [Member] | Corporate Notes and Bonds [Member] | Significant Unobservable Inputs (Level 3) [Member]
Assets measured at fair value on a recurring basis
Financial assets	0
Fair Value, Measurements, Recurring [Member] | U.S. Government and Agency Securities [Member]
Assets measured at fair value on a recurring basis
Financial assets	3,503	799
Fair Value, Measurements, Recurring [Member] | U.S. Government and Agency Securities [Member] | Significant Other Observable Inputs (Level 2) [Member]
Assets measured at fair value on a recurring basis
Financial assets	3,503	799
Fair Value, Measurements, Recurring [Member] | U.S. Government and Agency Securities [Member] | Significant Unobservable Inputs (Level 3) [Member]
Assets measured at fair value on a recurring basis
Financial assets	0
Fair Value, Measurements, Recurring [Member] | Commercial Paper [Member]
Assets measured at fair value on a recurring basis
Financial assets	3,283	798
Fair Value, Measurements, Recurring [Member] | Commercial Paper [Member] | Quotes Prices in Active Markets for Identical Assets (Level 1) [Member]
Assets measured at fair value on a recurring basis
Financial assets	0
Fair Value, Measurements, Recurring [Member] | Commercial Paper [Member] | Significant Other Observable Inputs (Level 2) [Member]
Assets measured at fair value on a recurring basis
Financial assets	3,283	$ 798
Fair Value, Measurements, Recurring [Member] | Commercial Paper [Member] | Significant Unobservable Inputs (Level 3) [Member]
Assets measured at fair value on a recurring basis
Financial assets	$ 0

Investments (Details)

Investments (Details) $ in Thousands	Dec. 31, 2016USD ($)
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	$ 25,635
Gross unrealized gains	0
Gross unrealized losses	(28)
Fair value	25,607
Corporate Note Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	18,846
Gross unrealized gains	0
Gross unrealized losses	(25)
Fair value	18,821
US Government Corporations and Agencies Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	3,506
Gross unrealized gains	0
Gross unrealized losses	(3)
Fair value	3,503
Commercial Paper [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	3,283
Gross unrealized gains	0
Gross unrealized losses	0
Fair value	$ 3,283

Investments (Details 1)

Investments (Details 1) $ in Thousands	Dec. 31, 2016USD ($)
Companies available-for-sale investments
Due in one year or less, Amortized cost	$ 25,635
Due after one year through two years, Amortized cost	0
Amortized cost	25,635
Due in one year or less, Fair value	25,607
Due after one year through two years, Fair value	0
Fair value	$ 25,607

Investments (Details Textuals)

Investments (Details Textuals) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2016USD ($)
Advanced Liquid Logic, Inc. [Member]
Schedule of Available-for-sale Securities [Line Items]
Realized gain	$ 1,392

Selected Quarterly Financial 74

Selected Quarterly Financial Data (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Selected Quarterly Financial Data
Total revenue	$ 14,885	$ 10,813	$ 12,512	$ 11,064	$ 13,186	$ 8,472	$ 7,646	$ 10,107	$ 49,274	$ 39,411	$ 30,594
Gross profit (loss)	8,642	6,451	7,792	6,689	8,498	5,120	4,360	6,116	29,574	24,094	17,467
Loss from operations	(12,058)	(11,627)	(12,588)	(12,708)	(8,461)	(11,117)	(11,930)	(10,027)	(48,981)	(41,535)	(39,054)
Net loss	$ (12,678)	$ (12,058)	$ (12,907)	$ (12,958)	$ (8,782)	$ (11,394)	$ (12,152)	$ (9,869)	$ (50,601)	$ (42,197)	$ (38,263)
Per share data:
Net loss per common share - basic and diluted	$ (0.27)	$ (0.27)	$ (0.30)	$ (0.30)	$ (0.21)	$ (0.27)	$ (0.29)	$ (0.24)	$ (1.15)	$ (1)	$ (0.93)

Subsequent Evens Debt Amendment

Subsequent Evens Debt Amendment Subsequent Event (Details)	Feb. 27, 2017	Dec. 31, 2016
Subsequent Event [Line Items]
Subsequent Event, Date	Feb. 27, 2017
Debt Interest only Period End		Mar. 1, 2017
June 1, 2017 Option [Member]
Subsequent Event [Line Items]
Debt Interest only Period End	Jun. 1, 2017
August 1, 2017 Option [Member]
Subsequent Event [Line Items]
Debt Interest only Period End	Aug. 1, 2017
March 1, 2018 Extension [Member] [Member]
Subsequent Event [Line Items]
Debt Interest only Period End	Mar. 1, 2018